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BACKGROUND: The biological basis for Frailty remains unclear. It is 
hypothesized that loss of bone mass, decline in protein synthesis, sarcopenia and 
immune dysfunction influence the onset of frailty. Studies show that low serum 
DHEA levels are associated with increased rates of morbidity and mortality. Serum 
levels of DHEA decline with age, and this decline is paralleled by a decrease in 
muscle and bone mass. Hence we take up this study to test the hypothesis that 
declining serum DHEA is associated with the frailty phenotype.  
 
AIMS & OBJECTIVES: To evaluate the association between 
Dehydroepiandrosterone (DHEA) and Frailty in the elder population. 
 
METHODS: The study group includes elderly subjects > 65 yrs, in the Geriatric 
ward of Rajiv Gandhi Govt. General Hospital, Chennai, who complied with the 
inclusion and exclusion criteria. Anthropometric evaluation was done. Fried’s 
criteria was employed to assess the frailty phenotype. Patients were categorized 
into 3 groups based on the number of frailty components - FRAIL (≥ 3 
characteristics); INTERMEDIATE FRAIL (1-2 characteristics); NON-FRAIL (no 
characteristic). Blood samples of patients from each group were collected for 
estimating serum DHEA-s level (using CLIA method) and analysis was performed 
by appropriate statistical methods. 
 
RESULTS: In a study conducted in 100 participants, a significant association 
between Frailty phenotype and DHEA level was observed (p < 0.0004). Ordinal 
logistic regression was used to model the relationship between frailty and DHEA, 
adjusting for age, gender and BMI. A significant DHEA–BMI interaction 
(OR=1.09; 95% CI; p = 0.0001) suggested that, in general, the relationship 
between higher levels of frailty decreased relative to higher levels of DHEA, but 
the magnitude of decrease was larger at lower BMI values and smaller at higher 
BMI values. A BMI >29 kg/m² attenuated the association between DHEA levels 
and frailty. 
 
 
CONCLUSION: This study found an inverse association between frailty and 
DHEA-s levels, similar to other studies that have found associations between 
DHEA-s and physical function. Whether the inverse association is due to similar 
conditions resulting in lower DHEA levels and more susceptibility to frailty or 
whether lower DHEA levels have an impact on increasing frailty cannot be 
addressed by this cross-sectional analysis.  
 
 
KEYWORDS: Frailty, Dehydroepiandrosterone sulphate (DHEA-s), Fried’s 
criteria, Body Mass Index (BMI)  
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INTRODUCTION 
Frailty is a common geriatric syndrome that embodies an increased risk of 
catastrophic declines in health and function among older adults. Frailty is a 
condition associated with aging, and it has been recognized for centuries. As 
described by Shakespeare in As You Like It, "the sixth age shifts into the lean and 
slippered pantaloon, with spectacles on nose and pouch on side, his youthful hose 
well saved, a world too wide, for his shrunk shank". The shrunk shank is a result of 
loss of muscle with aging. It is also a marker of a more widespread syndrome of 
frailty, with associated weakness, slowing, decreased energy, lower activity, and, 
when severe, unintended weight loss. 
 Estimates of frailty prevalence in older populations may vary according to a 
number of factors, including the setting in which the prevalence is being estimated 
e.g., nursing home (higher prevalence) vs. community (lower prevalence), and the 
operational definition used for defining frailty. Using the widely used frailty 
phenotype framework proposed by Fried et al (2001), prevalence estimates of 
about 7-16% have been reported in non-institutionalized, community-dwelling 
older adults. 
The occurrence of frailty increases incrementally with advancing age, and is 
more common in older women than men, and among those of lower socio-
economic status. Frail older adults are at high risk for major adverse health 
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outcomes, including disability, falls, institutionalization, hospitalization, and 
mortality. 
Epidemiologic research to date have led to the identification of a number of 
risk factors for frailty, including: (a) chronic diseases, such as cardiovascular 
disease, diabetes, chronic kidney disease, depression, and cognitive 
impairment; (b) physiologic impairments, such as activation of inflammation and 
coagulation systems, anemia, atherosclerosis, autonomic dysfunction, hormonal 
abnormalities, obesity, hypovitaminosis-D in men, and environment-related factors 
such as life space and neighborhood characteristics. Advances about potentially 
modifiable risk factors for frailty now offer the basis for translational research 
effort aimed at prevention and treatment of frailty in older adults. 
Recent work on frailty has sought to characterize both the underlying 
changes in the body and the manifestations that make frailty recognizable. It is 
well-agreed upon that declines in physiologic reserves and resilience is the essence 
of being frail. Similarly, scientists agree that the risk of frailty increases with age 
and with the incidence of diseases. Beyond that, there is now strong evidence to 
support the theory that the development of frailty involves declines in energy 
production, energy utilization and repair systems in the body, resulting in declines 
in the function of many different physiological systems. This decline in multiple 
systems affects the normal complex adaptive behavior that is essential to 
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health and eventually results in frailty typically manifesting as a syndrome of a 
constellation of weakness, slowness, reduced activity, low energy and unintended 
weight loss. When most severe, i.e. when 3 or more of these manifestations are 
present, the individual is at a high risk of death. 
 
BIOLOGICAL UNDERPINNINGS 
 It has been suggested that the biological underpinnings of frailty are 
multifactorial, involving dysregulation across many physiological systems. A pro-
inflammatory state, sarcopenia, osteoporosis, anemia, relative deficiencies in 
anabolic hormones (androgens and growth hormone) and excess exposure to 
catabolic hormones (cortisol), insulin resistance, compromised altered immune 
function, micronutrient deficiencies and oxidative stress are each individually 
associated with a higher likelihood of frailty. Additional findings show that the risk 
of frailty increases with the number of dysregulated physiological systems in a 
nonlinear pattern, independent of chronic diseases and chronologic age, suggesting 
synergistic effects of individual abnormalities that on their own may be relatively 
mild. The clinical implication of this finding is that interventions that affect 
multiple systems may yield greater, synergistic benefits in prevention and 
treatment of frailty than interventions that affect only one system.  
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Associations between specific disease states are also associated with and 
frailty have also been observed, including cardiovascular disease, diabetes 
mellitus, renal insufficiency and other diseases in which inflammation is 
prominent. To the extent that dysregulation across several physiologic systems 
underlie the pathogenesis of the frailty, specific disease states are likely concurrent 
manifestations of the underlying impaired physiologic function and regulation. It is 
possible that clinically measurable disease states can manifest themselves or be 
captured prior to the onset of frailty. No single disease state is necessary and 
sufficient for the pathogenesis of frailty, since many individuals with chronic 
diseases are not frail. Therefore, rather than being dependent on the presence of 
measurable diseases, frailty is an expression of a critical mass of physiologic 
impairments. 
It has been recently demonstrated that serum levels of single hormones such 
as testosterone, DHEA-s, and IGF-1 are predictors of metabolic syndrome, frailty 
and mortality. Evidence in support of the hypothesis that aging is associated with 
dysregulation of different components of the homeostatic network is emerging 
rapidly, especially for biomarkers of inflammation and nutritional status. Through 
studying the relationship between and among elements of this paradigm, we will 
better understand the age-related pathway to frailty and progressive disability. 
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Little is known about the physiological role of DHEA, but human 
epidemiological studies have suggested that its concentrations may represent a 
biomarker of successful ageing. Studies show that low serum DHEA levels are 
associated with increased rates of morbidity and mortality. Serum levels of DHEA 
decline with age, and this decline is paralleled by a decrease in muscle and bone 
mass[1,2,3]. 
Hence we take up this study to test the hypothesis that declining serum 
DHEA is associated with the frailty phenotype. 
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AIMS AND OBJECTIVES 
To evaluate the association between Dehydroepiandrosterone (DHEA) and 
Frailty in the elder population. 
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REVIEW OF LITERATURE 
 
 The Geriatric syndrome of Frailty is defined as a loss of reserve and is 
characterized by weight loss, fatigue, weakness and vulnerability to adverse events, 
which predict increased morbidity and mortality. It has been hypothesized that loss 
of bone mass, decline in protein synthesis, sarcopenia and immune dysfunction 
influence the onset of frailty[4,5]. 
  
FRAILTY AS A SYNDROME 
 Geriatricians have long been aware of a syndrome of multiple coexisting 
conditions, weakness, immobility, and poor tolerance to physiologic or 
psychologic stressors. People so affected are often characterized as “frail” and are 
known to be more vulnerable to poor health outcomes, including disability, social 
isolation, and institutionalization. Although frailty is more prevalent in older 
people and in those with multiple medical conditions, it can exist independently of 
age, disability, or disease, and may be an independent physiologic process 
involving multiple systems. 
 
DEFINITIONS OF FRAILTY  
 Frailty represents a form of predisability. In 1990, Fretwell stated “frailty in 
an individual is defined as an inherent vulnerability to challenge from the 
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environment.” Because of the high-risk status of frail older adults, geriatric 
medicine seeks to intervene in frail patients to prevent or minimize illness and 
dependency. In 1992, a conference on the physiologic basis of frailty agreed that 
controversy on definition and limited understanding of etiology hindered 
preventive strategies. In 1993,W. Bortz stated that a major threat to active life 
expectancy is the development of frailty. Baltes and Smith observed that the oldest 
old, those in the “fourth age” after 85 years (in developed countries), are 
particularly biologically vulnerable and frail and have compromised ability to 
tolerate stressors. As a result, their well-being is increasingly dependent on the use 
of extrinsic compensations to maintain life and autonomy, because there is such 
diminished ability to compensate physiologically. These observations frame the 
conceptual understanding that aging is associated with increased likelihood of 
frailty, and that older persons have reduced physiological reserve than younger 
persons and these changes are likely independent of disease. In 2001, Frailty has 
been objectively defined by Linda Fried and her colleagues at John’s Hopkins 
University. Their definition includes weight loss, exhaustion, weakness, walking 
speed, and low physical activity[6]. By this definition, approximately 6.9% of the 
older population are frail. Females are more often classified as frail than are males 
of the same age. Frailty is the beginning of a cascade that leads to functional 
deterioration, hospitalization, institutionalization, and death. 
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Frailty is the most problematic expression of population ageing. It is a state 
of vulnerability to poor resolution of homoeostasis after a stressor event and is a 
consequence of cumulative decline in many physiological systems during a 
lifetime. This cumulative decline depletes homoeostatic reserves until minor 
stressor events trigger disproportionate changes in health status.  
 
 
 
 
The picture depicts the varied resilience of a fit and frail elder person to 
stress.  
  
 Figure 2 - FRAILTY & DEPENDENCY 
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FRAILTY IS AT THE CORE OF GERIATRIC MEDICINE 
1) Frail older persons are at risk for multiple adverse health outcomes including 
 a) Medical instability 
 b) Disability 
c) Dependency 
 d) Institutionalization 
 e) Injuries 
 f) Falls 
 g) Acute illness 
 h) Hospitalization 
 i) Health care resources utilization 
 j) Slow or incomplete recovery from illness and/or hospitalization 
 k) High risk of iatrogenesis and side effects from medical interventions 
 l) Mortality 
2) The prevalence of frailty increases dramatically with age. 
3) Frailty is manifested as an impaired ability to cope with challenges in 
    health and reduced ability to regain a stable health status, possibly 
    related to reduced functional reserve. Severity of frailty spans from 
    subclinical to a clinical stage to impending death[7]. 
4) In aging individuals, the variability in health and functional status is 
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    explained less and less by the effect of clinically evident or even 
    subclinical diseases. Older age is associated with increased vulnerability 
    to multiple diseases with no evident pathogenetic connections. Such 
    global vulnerability is not explained by changes in recognizable risk factors. 
5) Frail older persons require intensive and multidimensional continuous care 
    and have high need of community and informal support services. These 
    care needs necessitate a shift in the deployment of heath care resources. 
6) Geriatrics is a medical specialty particularly skilled in the care of frail elders. 
 
CONCEPT OF FRAILTY: WHY IS IT COMPELLING? 
 First, frail individuals are perceived to constitute those older adults at 
highest risk for a number of adverse events, including disability, dependency, 
institutionalization, falls, injuries, acute illness, hospitalizations, slow or 
incomplete recovery from illness and/or hospitalization, and mortality. 
Additionally, they have compromised ability to tolerate hospitalization or invasive 
procedures and are at high risk of related complications[7].  
 Second, frail older adults are thought to be a subset in high need of health 
care and community and informal support services, as well as long-term care. 
These special needs were the main basis for the development of comprehensive 
geriatric assessment and creation of specific geriatric systems for care delivery as 
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optimal clinical approaches to decreasing preventable adverse outcomes for frail 
older adults.  
 Third, the prevalence of frailty is high, with estimates ranging from 10% to 
25% of persons aged 65 years and older, with as many as 30% to 45% of those 
aged 85 years and older identified as frail. Such estimates are based on clinical 
perceptions of a notable change in vulnerability, health status, and clinical 
appearance with age in a substantial subset of older adults that is not explained by 
disease alone.  
 Fourth, it is thought that the increased risk of adverse outcomes associated 
with frailty is a result of an increased vulnerability to stressors itself caused by a 
decreased ability to maintain homeostasis when the individual is stressed. Stressors 
can be intrinsic, such as infection, or extrinsic, such as change in environment. 
There is some evidence to suggest that, in addition to those who already appear 
frail clinically, a subset of older individuals have subclinical frailty, i.e., have 
increased vulnerability to adverse outcomes in the face of stressors but without the 
clinical stigmata of frailty or any of its outcomes.  
  A fifth reason that the concept of frailty has had saliency for geriatricians is 
the mounting evidence that there is a decrease with age in the ability of disease 
alone to explain the increased variation in health status, outcomes, or response to 
therapy. Measures of subclinical organ system changes and physical functional and 
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cognitive variables, rather than presence or absence of diseases, are the most 
powerful predictors of longevity and functional outcomes.  
 Sixth, with increasing age, there is a concurrent, increased susceptibility to 
multiple chronic diseases that is not explained by “classic” risk factors. This 
increased susceptibility with no evident pathogenetic connections in risk between 
the multiple diseases could be related to the progressive collapse of the regulatory 
network of biological signals aimed at maintaining the homeostatic equilibrium. 
Seventh, given the discussion above, it would appear that frailty is a condition of 
impending deterioration in health and functional status that requires immediate 
attention to prevent disability and other associated outcomes. It requires substantial 
clinical expertise to both recognize those who are frail and/or vulnerable, and 
accurately diagnose and effectively intervene to prevent adverse outcomes or 
frailty itself. Because of the complexity of presentation, attendant vulnerabilities, 
and multiple health problems likely to be concurrently present, health care in frail 
older people needs to be skilled, intensive, and continuous to be effective and, 
therefore, is intrinsically more expensive[7,49]. 
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CONTINUUM OF RESILIENCE - FRAILTY IN OLDER ADULTS 
 Some clinical reports indicate that there is a subset of older adults with 
advanced frailty stigmata and significant outcomes, particularly disability or 
dependency, who have lost reserves and resilience to a point that they have a very 
high likelihood of dying within 6 to 12 months, and are quite unlikely to respond to 
therapies, including rehabilitative therapies. These differentiations of 
vulnerability—with or without the clinical appearance of frailty and its sequelae—
are consistent with the idea of a continuum of frailty among older adults as a core 
component underlying the heterogeneity of health status observed with increasing 
age. This continuum of frailty incorporates what is thought clinically to be a 
distinct causal pathway to disability, with frailty being a major etiologic risk factor 
independent of disease[7,8,13]. Frailty is thought distinguishable from disability (as 
an outcome) and comorbidity, although there are overlapping co-prevalences[45]. 
                  
   Figure 3 – CONTINUUM OF RESILIENCE - FRAILTY 
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Sub-clinically 
frail 
Early Frailty Late Frailty End stage 
 Frailty 
Resilient; 
recovers 
readily from 
stressors. 
Appears 
resilient, but 
recovers 
slowly or 
incompletely 
from stressors 
& may 
manifest 
adverse 
consequences. 
Clinical 
appearance 
of being frail 
Poor tolerance 
of stressors; 
no disability. 
Clinical 
appearance 
of being frail 
Poor tolerance 
of stressors 
very slow 
recovery 
Outcomes: 
disability due 
to decreased 
energy, 
strength. 
Clinical 
appearance 
of severe 
frailty; 
low LDL, 
cholesterol, 
strength; 
weight loss 
Outcomes: 
dependent; 
high risk of 
death < 1 yr. 
Table 1 - CONTINUUM OF RESILIENCE - FRAILTY 
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PATHOPHYSIOLOGY OF FRAILTY 
 Weakness and fatigue are central to almost all definitions of frailty. 
Sarcopenia (loss of skeletal muscle mass) is likely a key component of these 
symptoms[7]. 
 
 
                 Figure 4 – PATHOPHYSIOLOGY OF FRAILTY 
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Effects of endocrine changes 
 Changes in the endocrine system play a role in the accelerated decline in 
muscle mass and strength seen in frail older adults. In women, sex hormone levels 
decline fairly abruptly with the onset of menopause; in men testosterone levels also 
decline, but less abruptly[9]. Growth hormone levels also decrease with age. 
Compared with non-frail older adults, frail older adults have lower levels of the sex 
hormone dehydroepiandrosterone sulfate (DHEA-s) and insulin-like growth factor-
1 (IGF-1), a messenger molecule stimulated by growth hormone. Lower levels of 
IGF-1 have been shown to be associated with lower strength and decreased 
mobility in a cohort of community- dwelling older women[14]. Many other 
hormones and nutrients, including vitamin D, have been shown to preserve muscle 
strength and hence may play a role in preventing or treating frailty. 
 
Effects of inflammation 
 Markers of inflammation are also associated with the frailty syndrome. 
Serum levels of interleukin 6 (IL-6) and C-reactive protein have been found to be 
elevated in community-dwelling frail older adults[14]. IL-6 is strongly associated 
with adverse physiologic effects such as sarcopenia, weight loss, and an increased 
susceptibility to infection. In addition, IL-6 may contribute to anemia by directly 
inhibiting production of erythropoietin or by interfering with normal iron 
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metabolism. In a cohort of community-dwelling older adults, subclinical 
normocytic anemia was observed in those who were frail, and an inverse 
correlation was found between serum IL-6 and hemoglobin levels. This chronic 
inflammatory state likely also contributes to other hematologic effects such as 
activation of the clotting cascade[39]. Indeed, frail older adults have been found to 
have significantly elevated levels of factor VIII, fibrinogen, and D-dimer. 
 
 
 
Figure 5 – ENDOCRINE CHANGES & FRAILTY 
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Interaction of systemic changes is likely 
 The physiologic findings and other features that characterize frailty are not 
likely to be the result of changes in a single system, but rather of the interaction of 
several systems resulting in a global process[25]. For example, the combination of 
low IGF-1 and high IL-6 levels in a cohort of community- dwelling older women 
conferred a high risk for progressive disability and death that was greater than the 
effect of either of these two factors alone, suggesting an additive effect. Similarly, 
Roubenoff showed that increased cellular production of tumor necrosis factor 
alpha and IL-6 and decreased cellular production of IGF-1 were associated with 
increased death rates over 4 years in a cohort of community-dwelling older adults. 
These findings persisted after adjusting for potential confounders such as chronic 
disease. 
 
Factors influencing frailty[8] 
 Disease 
 Diabetes mellitus 
 Chronic obstructive pulmonary disease 
 Anemia 
  Polymyalgia rheumatica 
  Endocrine disorders 
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 Decline in executive function 
 Decreased food intake 
  Social factors 
 Congestive heart failure 
 Decline in taste and smell 
 Altered fundal compliance 
  Enhanced release of cholecystokinin 
  Increased leptin 
 Cytokines 
 Pain 
 Excess muscle loss (Sarcopenia) 
 Lack of physical activity 
  Poor nutritional intake 
 Decline in anabolic hormones 
 Increased cytokines 
 Reduced nerve motor units 
 Peripheral vascular disease 
 Age 
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Disease 
 Numerous disease processes can directly or indirectly result in frailty. Many 
diseases produce excess of cytokines that can lead to decreased muscle mass, food 
intake and cognitive function. Diseases also lead to a decline in levels of the 
anabolic hormone, testosterone.  
 Congestive heart failure (CHF) is a condition that is classically associated 
with frailty. Persons with CHF have a marked decline in their VO2 max, leading to 
an inability to perform endurance tasks. Left-sided heart failure leads to intestinal 
wall edema.  
            
      Figure 6 – CCF & FRAILTY 
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This results in bacterial translocation into the lymphatic and systemic circulation. 
The bacterial endotoxins (LPS) result in the activation of the immune system and 
release of cytokines, such as TNF α[18]. This results in anorexia, loss of muscle 
mass, weight loss, hypoalbuminemia, and hypocholesterolemia. In CHF, the best 
predictors of poor outcome are weight loss and hypocholesterolemia. Activation of 
the angiotensin II system that leads to cleaving of actomyosin and subsequent 
clearance of muscle protein by the ubiquitin-proteasome system may also play a 
role. Angiotensin-converting enzyme inhibitors reverse weight loss and frailty in 
some persons with CHF.  
 Persons with chronic obstructive pulmonary disease have a decrease in 
endurance, weight loss due to poor food intake[68], and increased resting metabolic 
rate and thermic energy of eating. They lose muscle because of low testosterone 
levels and increased circulating cytokine levels.  
 Diabetes mellitus is classically associated with an increase in frailty, 
injurious falls, disability and premature death[20,42]. Again, the causes are 
multifactorial and include low testosterone, increased angiotensin II, increased 
cytokines, peripheral neuropathy, reduced executive function and accelerated 
atherosclerosis[72].  
 Persons with anemia have reduced endurance[46], decreased muscle strength, 
orthostasis, increased falls, increased frailty, decreased mobility, increased 
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disability and increased mortality. Both erythropoietin and darbopoetin-α can 
reverse the anemia and many of these changes. The use of these agents has led to a 
marked increase in the quality of life of patients with chronic kidney failure, 
anemia of chronic disease, and myelofibrosis. 
 Polymalgia rheumatica is a condition associated with painful muscles and 
proximal myopathy. It is confirmed by an elevated erythrocyte sedimentation rate. 
Treatment of this condition with corticosteroids can reverse the frailty it produces. 
Unfortunately, this totally reversible condition is often misdiagnosed by clinicians. 
 Endocrine disorders, such as Addison’s disease, hyperthyroidism and 
hypothyroidism can have insidious onset in elderly individuals. When this occurs, 
they are the classical causes of frailty. 
 
Pain 
 Joint pain (arthritides) is classically associated with immobility. Immobility, 
over a period of time, leads to loss of muscle mass and power and to a decline in 
endurance, the hallmarks of frailty. Pain can further induce frailty secondary to 
aggravating depression in elders. 
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Figure 7 - CYCLE OF FRAILTY  
Integrating causal relationships between signs and symptoms[8]. 
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Sarcopenia 
 Sarcopenia (from the Greek meaning "poverty of flesh") is the excessive 
loss of muscle mass that occurs in older persons. It is usually defined as a greater 
than two standard deviations amount of lean tissue loss compared to that of 
younger persons[23,37]. It occurs in 13–24% of persons aged 60–70 years and in 
about 50% over 80 years of age[23,34,35]. The best measure of sarcopenia is based on 
the appendicular skeletal mass in kilograms as measured by DEXA, divided by the 
height in meters squared. It can also be calculated using magnetic resonance 
imaging (MRI), computed tomography (CT), or bioelectrical impedance. DEXA 
and MRI measures are highly correlated. Sarcopenia is strongly correlated with 
disability[37]. Most sarcopenic individuals have lost fat as well. However, a subset 
of individuals remain fat while losing muscle mass. These individuals have been 
characterized as the “sarcopenic obese” or the “fat frail”[27]. Longitudinally, those 
with obese sarcopenia have been found to be the most likely to develop future 
disability and mortality[37]. Myosteatosis – the infiltration of fat into muscle – 
appears to be a separate condition related to insulin resistance. Mitochondrial 
failure or elevated circulating triglycerides lead to accumulation of triglycerides 
within the cell. This alters the function of the insulin receptor substrate and, 
therefore, the GLUT transporter, leading to insulin resistance. The development of 
sarcopenia and its effect on frailty have been characterized in the worm 
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Caenorhabditis elegans. In C. elegans, muscle deterioration (sarcopenia) with 
aging leads to a decline in body movement. The muscle deterioration also 
correlates with behavior deficits (a frailty equivalent). These changes rarely 
correlated with a decreased life span. Mutations in daf-2 (the worm’s IGF-1) delay 
these changes. 
 Sarcopenia of aging is not explained entirely on the basis of age-associated 
reduced physical activity. Progressive neuromuscular changes and diminishing 
anabolic hormone levels are thought to contribute to the pathogenesis of 
sarcopenia. Decline in muscle mass indicates a decline in muscle protein content. 
Recent studies demonstrated an age-related decline in synthesis rate of mixed 
muscle proteins, myosin heavy chain and mitochondrial protein. Reductions in 
myosin heavy chain and mitochondrial protein synthesis rates have been correlated 
with age-associated decrements in muscle strength and aerobic exercise tolerance, 
respectively. These changes have been reported as early as 50 years of age and are 
related to the decline in insulin-like growth factor (IGF-1), testosterone and 
dehydroepiandrosterone sulfate (DHEA-s). The declining ability to remodel these 
important muscle proteins may therefore play a role in the development of muscle 
wasting, metabolic abnormalities and impaired physical functioning seen in old 
age[11,12,26]. 
 28 
 
There is evidence that sarcopenia originates at birth. In the Hertfordshire 
cohort study, it has been shown that grip strength correlates with birth weight. 
Genetic studies have shown that persons with a single I or double I allele for 
angiotensin-converting enzyme appear to be able to generate more power when 
exercising regularly than those with D allele.  
 Epidemiological studies have suggested that the best predictors of muscle 
mass and strength in older persons are age, energy intake, physical activity, IGF-1, 
testosterone, and cytokines[21,30,37]. Testosterone levels decline at the rate of 1% per 
year from the age of 30 years in men and rapidly between 20 and 40 years in 
women[33,66]. Testosterone inhibits the movement of pluripotential stem cells into 
the fat cell lineage and stimulates the muscle cell lineage to result in the production 
of satellite cells. Satellite cells are essential for the repair of skeletal muscle[22]. 
Testosterone also stimulates muscle protein synthesis and inhibits the ubiquitin-
proteasome pathway, resulting in a decrease in muscle protein turnover. 
Testosterone replacement, even in non-hypogonadal males, increases muscle 
mass[25]. 
Pharmacological doses of testosterone or testosterone replacement in 
hypogonadal males lead to an increase in muscle strength and muscle power. These 
changes have now been shown to lead to functional improvement. However, there 
is a small amount of evidence that testosterone has similar effects in older women.  
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A number of selective androgen receptor molecules (SARMs) are being 
developed, in an attempt to find androgenic compounds that have a specific effect 
on muscle but are less likely to produce side effects.   
 Steroids      Nonsteroidal 
 -Nandrolone      -2-Quinoline 
 -Oxymethalone     -Coumarin 
 -Oxandrolone     -Phthalimide 
        -Acetothiolutamide 
        -Bicalcutamide 
 Another anabolic hormone, Growth Hormone, increases muscle mass but not 
strength in older persons. The effect of growth hormone is predominantly on type-
II muscle fibers. 
  Ghrelin, a growth hormone secretagogue produced in the fundus of the 
stomach, also appears to increase muscle mass.  
 Insulin growth factor (IGF) is produced in three alternative forms in muscle. 
One of these forms, a mechanogrowth factor (MGF) is produced in response to 
mechanical overload. The ability of MGF to be produced in response to 
mechanical overload declines with aging. Resistance exercise increases MGF in 
human quadriceps[24], and this increase is greater when growth hormone is also 
given. IGF enhances satellite cell production. 
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 Myostatin D inhibits muscle growth. A double deletion of myostatin D in 
mice leads to muscle hypertrophy, a veritable “mighty mouse”. Motor unit 
functioning is essential for the maintenance of muscle function. Motor unit firing 
rate is significantly decreased in the old-old, that is, those over 80 years of age.  
 Ciliary neurotrophic factor (CNTF) levels decline with age and this decline 
correlates with the decrease in muscle strength with aging. Administration of 
CNTF leads to twofold increase in soleus muscle size.  
 Cytokines are soluble peptide messengers that are synthesized by white 
cells, neuronal cells and adipocytes. Excess of tumor necrosis factor-α and 
interleukin-6 leads to loss of muscle strength. High levels of C-reactive protein and 
interleukin-6 are associated with a decrease in handgrip strength and in physical 
performance. 
       
                  Figure 8 – FRAILTY & SARCOPENIC OBESITY 
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Elevated homocysteine levels and peripheral vascular disease lead to 
reduced blood flow to muscles which causes muscle atrophy and decreased 
function. Creatine is an essential amino acid for muscle. Creatine, together with 
exercise, may improve muscle performance in older persons. Finally, the 
development of sarcopenia depends on an imbalance in the normal everyday 
renewal cycle of muscle. There is either an excess of atrophy and apoptosis or a 
diminution of hypertrophy and satellite cell production. 
 
     
 
 
 
Figure 9 – VENN DIAGRAM DEPICTING RELATIONSHIP       
       BETWEEN FRAILTY & SARCOPENIA 
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Decreased Food Intake 
 Older persons develop anorexia of aging physiologically that is associated 
with a loss of weight. Social causes, such as isolation and dysphoria, and the 
decline in smell and increase in taste threshold are other causes. Recently, there 
have been a number of studies that demonstrated that decreased compliance and 
adaptive relaxation of the stomach results in a more rapid antral filling and early 
satiety. Cholecystokinin produced by the duodenum in response to a fatty meal is 
another cause of anorexia in elders. High circulating cytokine levels in older 
persons have been associated with anorexia. With advancing age, males have a 
greater decrease in both absolute and relative amounts of food intake. This appears 
to be due to the fall in testosterone level, which results in an increase in leptin level 
and, therefore, a greater anorexia[68]. 
 
 
 Figure 10 – ANOREXIA & FRAILTY 
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SYNDROMIC NATURE OF FRAILTY 
There are inputs at multiple levels including (1) biologic, (2) altered 
physiological functions in homeostatic systems and altered communications 
systems, and then (3) a clinical presentation that appears to be the outcome of these 
multiple changes and constitutes a constellation of presentations that are 
interrelated in themselves and likely involved in a vicious cycle of dysregulated 
energetics. The aggregate impact of dysfunction at multiple levels is thought to 
result in compromised ability of the organism to maintain homeostasis and the 
vulnerability to stressors manifested by frail older adults[7,10]. 
        
 
 
Figure 11 - SYNDROMIC NATURE OF FRAILTY 
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The clinical phenotype of frailty is based on proposed interrelationship of 
decline in physical activity level, performance, energy, strength and weight loss. 
Sarcopenia contributing to altered energy production and utilization is a well 
established fact. With loss of muscle mass and decreased muscle function, there is 
a decline in muscle strength and exercise tolerance. The latter can be validly 
represented by the concept of “fatigue” or “exhaustion.” Although it directly 
relates to the amount of physical work the individual can produce, “fatigue” or 
“exhaustion” may also directly result from altered cellular production or 
consumption of energy. Further, there is evidence that declines in strength and 
exercise tolerance predict both slower walking speed and further decreases in 
performance level. In a subset of elders, who maybe frail (although that is not yet 
demonstrated), there is a mismatch between inadequately low food intake and 
inadequately high energy expenditure through physical activity (even at low 
levels), resulting in further loss of muscle and, in cases extremely severe cases, 
weight loss. These interconnections support the concept of a “cycle” of frailty. 
There is now evidence that this cycle has a natural history of chronic progression 
that often begins with declines in strength and/or walking speed, which then 
predicts declines in physical activity[15,41]. However, when strength, walking speed, 
and physical activity are all impaired, then the system rapidly progresses toward 
frailty[7,40]. 
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A number of physiologic systems at abnormal levels have been shown to be 
associated with the frailty phenotype above[16,17,32]. These include sarcopenia and 
higher fat deposits in muscle, low testosterone, insulin, DHEA-s and IGF-1[36,63], 
blunted diurnal variation and higher levels of cortisol, insulin, elevated pro-
inﬂammatory markers (i.e., IL-6 and C-reactive protein [CRP]), elevated markers 
of blood clotting, anemia[46], low micronutrient levels (especially total carotenoids, 
beta carotene and lutein/zeaxanthin), decreased immune function[38] (with 
decreased T-cell proliferation and altered cytokine production), and decreased 
heart rate variability. Further, the severity of abnormality within each system and, 
particularly, the number of systems at abnormal levels are associated with the 
presence and severity of frailty. Frail older women are more likely to have two or 
more micronutrient deﬁciencies and low daily energy intake of 21 kcal/kg or less, 
along with low intake of protein, vitamins D, E, C, and folate. Thus, circulating 
antioxidants are low in those who are frail compared to non-frail[18,28,29]. New 
evidence indicates that the risk of frailty is highly associated with multiple systems 
at abnormal levels, signiﬁcantly more than any one system described above. The 
multiplicity of systems at abnormal levels is the hallmark of frailty. In spite of 
overwhelming evidence that age and frailty affect multiple physiological 
parameters in parallel, most research on biomarkers of aging is based on single 
measures.  
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STANDARDIZED APPROACHES TO ASCERTAIN FRAILTY 
Several approaches have been developed to identify those who are frail. 
One, developed by Rockwood and colleagues[43,48,71], described above, creates a 
summary measure of deﬁcit accumulation (termed “frailty index (FI)”)  across 
many different types of health conditions at many levels: functional, clinical, and 
physiological. It was designed to quantifying the theorized impact of aggregate 
disease and illness burden. The investigators have shown that increasing numbers 
of conditions present are associated with a stepwise increase in mortality risk. 
Inferentially, they theorize that the aggregate physiological effect of these multiple 
conditions is “frailty.” This approach has the two main disadvantages: the number 
of parameters to be collected makes it unsuitable for clinical utilization and, 
second, it does not offer a unifying theory as to etiology that might guide 
prevention and treatment. 
A second approach posits, consistent with discussion in the prior section, 
that there is a distinct pathophysiology to frailty with a syndromic clinical 
presentation. Several groups have proposed related approaches, building on the 
observation of characteristic signs and symptoms of people who are “frail.” In 
1999, Paw et al. posited that inactivity and malnutrition were two major 
determinants of frailty that jointly provide strong prediction of the adverse 
outcomes of frailty. In the Zutphen Elderly Study, they found the combination of 
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inactivity (less than 210 mins of physical activity per week) and weight loss (more 
than 4 kg over 5 years) identiﬁed 6% of this cohort of older men as “frail,” and 
predicted slow walking speed, and greater disability and mortality. By necessity, 
these authors used weight loss over 5 years, but identiﬁed this as a limitation to 
sensitivity and suggested use of weight loss over the last year instead. Overall, the 
authors claim that this approach offers a simple, inexpensive, and effective 
screening for identifying a frail population. 
In 1998, Fried and Walston[6,44] proposed that there were a few major 
presenting symptoms and signs of frailty, and that these were interrelated in a 
vicious cycle, or feed-forward loop, resulting from dysregulated energetics with 
declines in strength, energy, walking speed, physical activity, and weight loss (over 
1 year), all interrelated and presenting cardinal manifestations of a clinical 
syndrome of physical frailty.  
This proposal was subsequently operationalized by deﬁning the frail as those 
with a critical mass of clinical manifestations, i.e., three or more. This deﬁnition 
has been validated (face, criterion, construct, predictive) in more than ﬁve 
population-based studies as identifying those at high risk of disability, falls, 
hospitalization, hip fracture, and mortality. Further, this frailty phenotype has been 
shown to have characteristics of a medical syndrome, in which the multiplicity of 
signs and symptoms present identiﬁes those who are frail more than any one or 
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two. Risk of adverse outcomes is more strongly associated with the constellation of 
presentations than with any one or two and no speciﬁc cluster of criteria carry 
distinguishable risk. This approach to characterizing frail older adults is based on 
the theory of a discrete syndrome with speciﬁc deﬁnable causes, both biological 
and environmental. By this deﬁnition of frailty, prevalence is 7% overall in 
community-dwelling men and women aged 65 years and older, and increases with 
increasing age from 3% in those 65 to 74 years up to 25% in those 85 years and 
older. There is a twofold higher prevalence in African-American older adults, 
compared to whites, at each age group 65 years and older. Using this deﬁnition, 
there is now evidence as to the natural history of frailty, indicating it is a dynamic 
but generally chronic, progressive condition, with 43% transitioning to states of 
greater frailty over 18 months, while 23% transitioned to states of lesser frailty, 
and almost no one transition from frail to being non-frail. Further, initial 
presentations of frailty are most likely to be decreased strength or slow walking 
speed, which then predict development of additional manifestations, consistent 
with the hypothesis of a cycle of frailty. Those with one or two manifestations are 
at twofold higher risk of progressing to three, four, or ﬁve over 3 years, thus 
suggesting they are pre-frail. There is now strong evidence for the association of 
this clinical phenotype with dysregulation in number of physiologic systems. Thus, 
with this approach, frailty can be thought about in terms of a core phenotype 
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manifesting a syndrome, with deﬁnable outcomes and recognized etiology. 
Ongoing research aims to deﬁne the physiological alterations and the ultimate 
biological causes of frailty.  
As stated by Bergman[62], the underlying assumption of an operational 
deﬁnition of a syndrome, based on symptoms, is that domains used for the 
diagnosis do not represent all possible manifestations of the syndrome; rather, they 
constitute the important domains that can be easily and reliably measured and 
together maximize speciﬁcity of the diagnosis. Because many components of the 
pathological process are associated with each other, it is not necessary to require 
the presence of all of them to make the diagnosis. Consistent with this, these 
authors suggest that the phenotype described above, with distinct, standardizable 
measures and criteria for deﬁnition, built on biologic theory, validated with 
diagnostic criteria that are strongly age-related, lends itself for use in screening, 
diagnosis, and as a basis for prevention and treatment of frailty. A disadvantage of 
this particular deﬁnition, however, is that assessment requires approximately 10 to 
15 minutes: to weigh a patient, measure grip strength and walking speed, and to 
ask two questions regarding “exhaustion” and a physical activity questionnaire. 
Studenski and others advocate that measurements of walking speed and possibly 
strength should be considered geriatric “vital signs” and assessed regularly in 
clinical settings. If this is implemented generally in clinical practice, then the time-
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consuming part of this assessment is determining physical activity level; 
methodological work is needed to develop a more parsimonious approach to 
screening physical activity than current questionnaires offer.  
An alternative approach has been proposed for clinical characterization of 
patients as frail and using clinical judgment particularly to measure change over 
time clinically and/or in response to treatment. A global impression of change in 
frailty has been developed by Studenski and colleagues to represent the clinician’s 
perspective on clinically meaningful change resulting from interventions on 
physical frailty, e.g., nutrition, exercise, medications, and multifactorial 
approaches. This measure records clinician judgment regarding the domains of 
intrinsic frailty (strength, balance, nutrition, stamina, physical activity, neuromotor 
function, and mobility) plus appearance, medical complexity, perceived health, 
healthcare utilization, and outcomes of frailty (physical disability in basic, 
instrumental, and advanced functions; emotional status; and social status). Its goal 
is to create a reference point for deﬁning the magnitude of change in simple 
objective measures in order to eventually measure effects of interventions to 
prevent or treat frailty, integrating clinical meaning with traditional measurement 
properties[7].  
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REPORTED COMPONENTS OF THE FRAILTY SYNDROME  
 The components of frailty according to various references are tabulated[31]. 
  
REFERENCE MOBILITY STRENGTH BALANCE MOTOR PROCESSING COGNITION NUTRITION ENDURANCE 
PHYSICAL 
ACTIVITY Winograd CH et al.  X    X X  X Ory MG et al.  X X X  X  X  Pendergast DR et al.   X X X   X  Rockwood K et al.      X   X Tinetti ME et al.  X X       Gill TM et al.  X  X      Campbell AJ et al.   X X X X X X  Dayhoff NE et al.   X X      Strawbridge WJ et al.  X    X X   Chin APMJ et al.       X  X Vellas B et al.   X    X X X Brown M et al.  X X X X     Fried LP et al.  X X    X X X Saliba D et al.  X        
Table 2 - FRAILTY COMPONENTS AS PER VARIOUS REFERENCES 
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OBJECTIVE DEFINITION OF FRAILTY:  
 
FRIED’S CRITERIA: 
 
 A popular approach to the assessment of geriatric frailty encompasses the 
assessment of five dimensions that are hypothesized to reflect systems whose 
impaired regulation underlies the syndrome[6]. These five dimensions are:  
 Weight loss  
 Exhaustion  
 Weakness  
 Walking speed  
 Physical activity  
 
CUT-OFFS USED TO DEFINE FRAILTY: 
1) Weight loss:  
 In the past year have you lost more than 10 lb (5% of previous year’s body 
weight) unintentionally? (not due to dieting or exercise). If yes, subject is frail for 
weight loss criterion. 
 
2) Exhaustion:  
 Using the Centre for Epidemiological Study – Depression scale (CES-D), 
the following two statements are read. 
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1) I felt everything I did was an effort. 
2) I could not get going. 
 The question is asked. How often in the last week did you feel this way? 
 0 = rarely or none of the time (<1 day) 
 1= some or a little of a time (1-2 days) 
 2 = moderate amount of time (3-4 days) 
 3 = most of the time 
Subjects answering ‘2’ or ‘3’ to either of the question is categorized as frail 
by exhaustion criterion. 
 
 3) Physical activity:  
It is measured by the short version of minnesota leisure time physical 
activity questionnaire. This is a commonly used, interviewer-administered 
questionnaire that assesses daily physical activity accumulated during leisure time 
and household activities over the past 1 week. It takes about 20 minutes to 
complete the questionnaire. Physical activity was calculated based on the number 
of minutes spent in each specific activity per week. Physical activity energy 
expenditure (in kcal/week) was used for data analysis. 
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Male: Those with < 383 Kcal/week of physical activity are considered to be 
frail according to this criterion. 
 Female: Those with < 270 Kcal/week of physical activity are considered to 
be frail according to this criterion. 
 
4) Walking speed 
 Stratified by gender and height (gender specific cut off at median height). 
    Cut-off for time to walk 15 ft - criterion for frailty  
Male  
Height ≤ 173 cm    ≥ 7 s 
Height > 173 cm    ≥ 6 s 
 
Female 
Height ≤ 159 cm    ≥ 7 s 
Height > 159 cm    ≥ 6 s 
 
5) Grip strength:  
 It will be measured in the dominant hand using a Hand Dynamometer. Three 
attempts at maximal squeeze will be calculated. Average value will be stratified 
by gender and body mass index (BMI) quartiles. 
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    Cut-off for grip strength (kg) - criterion for frailty 
Male 
BMI ≤ 24     ≤ 29 
BMI 24.1-26    ≤ 30 
BMI 26.1-28    ≤ 30 
BMI > 28     ≤ 32 
 
Female 
BMI ≤ 23     ≤ 17 
BMI 23.1-26    ≤ 17.3 
BMI 26.1-29    ≤ 18 
BMI > 29     ≤ 21 
 
 
INFERENCE:  
A subject is frail if he/she has ≥ 3 components; Intermediate subjects have 1 
or 2 components; and subjects with 0 positive frailty factors are considered not 
frail. 
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BIOMARKERS OF FRAILTY  
One hallmark of frailty is the dysregulation of homeostatic or 
communications systems, at both the molecular and physiological level. As 
mentioned previously, declines in hormones important in muscle mass 
maintenance such as IGF-1 and DHEA-s, and increases in afternoon cortisol levels 
and in inﬂammatory and clotting markers, point toward the immune and 
neuroendocrine systems as likely candidates as the physiological source of this 
dysregulation[52]. 
Aging and frailty are associated development of a mild pro-inﬂammatory 
state, indicated by increased levels of pro-inﬂammatory markers. It has been 
demonstrated that, among non-disabled older persons, those in the highest IL-6 
tertile are at high risk of developing disability over a 4-year follow-up. Older 
persons with elevated IL-6 and high CRP had higher mortality and there is some 
evidence that a short-term increase in IL-6 is a strong, independent predictor of 
mortality. Additionally, some studies suggest that the causal link between 
inﬂammation and disability is accelerated sarcopenia. In accordance with this 
hypothesis, there is increasing evidence that inﬂammation is involved in the 
pathogenesis of age-related muscle wasting, perhaps by the up-regulation of the 
NF-κB activation of the ubiquitin proteasome pathway. Adiposity appears to play 
an important role in the inﬂammatory process, and, possibly, the onset of 
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sarcopenia. Studies have suggested that inﬂammatory cytokines produced by 
adipose tissue, especially visceral fat, accelerate muscle catabolism and may 
contribute to the vicious cycle that initiates and sustains sarcopenic obesity and 
may lead to frailty in older persons. There is cogent evidence of a connection 
between inﬂammation and frailty, but whether the link between these two 
conditions is completely explained by the effect of inﬂammation on sarcopenia is 
unclear. Inﬂammatory states also affect energy availability, hematologic, and 
hormonal status.  
A recent but robust literature suggests that inadequate intake of antioxidant 
and anti-inﬂammatory nutrients (in particular selenium, vitamin E, cholecalciferol, 
carotenoids, and polyunsaturated fatty acids (PUFAs) contribute to sarcopenia and 
decline in physical function in older persons. In the InCHIANTI baseline 
evaluation, plasma alpha-tocopherol, was signiﬁcantly correlated with knee 
extensor strength and lower extremity performance. Intake of vitamin C and beta-
carotene were signiﬁcantly correlated with knee extensor strength, and vitamin C 
was signiﬁcantly associated with lower extremity performance. In addition, low 
selenium level was independently associated with poor muscle strength and higher 
mortality. In the WHAS, low selenium level was a risk factor for mortality and 
future increase in inﬂammatory markers, and in conjunction with low vitamins B-6 
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and B-12, was an independent risk factor for mortality. Low alpha-tocopherol was 
an independent correlate of frailty and poor cognitive function. Both in WHAS and 
InCHIANTI, low carotenoids was an independent risk factor for accelerated 
decline of muscle strength and incident disability. Thus, deﬁcient intake of 
multiple nutrients is an independent correlate of frailty, even after adjusting for 
total energy intake. 
 Sirtuins are a class of proteins that possess NAD dependent deacetylase 
activity. They have been implicated in influencing a wide range of cellular 
processes like ageing, transcription, apoptosis, inflammation and energy 
homeostasis. Sirtuins can also control circadian clocks and mitochondrial 
biogenesis. Preliminary studies with resveratrol, a possible SIRT 1 activator, have 
led some scientists to speculate that resveratrol may extend lifespan. 
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Figure 12 - MODEL PATHWAY OF FRAILTY 
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DEHYDROEPIANDROSTERONE 
 
  
                                    
 
 
 
       Dehydroepiandrosterone (DHEA) more correctly didehydroepiandrosterone; 
also known as androstenolone is an important endogenous steroid hormone. Its 
chemical formula is C19H28O2 and molecular mass is 288.424 g/mol. It is the most 
abundant circulating steroid in humans, in whom it is produced in the adrenal 
glands, the gonads, and the brain, where it functions predominantly as a metabolic 
intermediate in the biosynthesis of the androgen and estrogen sex steroids. 
However, DHEA also has a variety of potential biological effects in its own right, 
binding to an array of nuclear and cell surface receptors, and acting as 
a neurosteroid. 
Dehydroepiandrosterone (DHEA) and its sulphate ester (DHEA-s) are 
prominent adrenal steroid hormones in humans. DHEA influences peripheral 
tissues either indirectly via a conversion to androgens, estrogens or both, or 
directly as a steroid hormone. DHEA shows a characteristic secretion pattern 
 Figure 13 – STRUCTURE OF DHEA 
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throughout life, with serum levels declining with increasing age. Serum DHEA 
levels peak in young adults and gradually decline throughout life, so that 
individuals 70– 80 years old have circulating DHEA levels that are 10–20% of 
their young adult levels[53]. This age-associated decrease has been termed 
‘adrenopause’ and differs from other adrenocortical hormones, which do not 
demonstrate clear age-related changes[36]. DHEA levels also vary with gender, with 
higher levels in men than in women[1,54,65]. 
 
DEHYDROEPIANDROSTERONE SULFATE 
 Dehydroepiandrosterone sulfate (DHEA-s) is the sulfate ester of DHEA. 
This conversion is reversibly catalyzed by sulfotransferase (SULT2A1) primarily 
in the adrenals, the liver, and small intestine. In the blood, most DHEA is found as 
DHEA-s with levels that are about 300 times higher than those of free DHEA. 
Orally ingested DHEA is converted to its sulfate when passing through intestines 
and liver. Whereas DHEA levels naturally reach their peak in the early morning 
hours, DHEA-s levels show no diurnal variation. From a practical point of view, 
measurement of DHEA-s is preferable to DHEA, as levels are more stable. 
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Figure 14 - DEHYDROEPIANDROSTERONE – BIOSYNTHESIS 
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MECHANISM OF ACTION OF DHEA: 
 Although it predominantly functions as an endogenous precursor to 
more potent androgens such as testosterone and DHT, DHEA has been found to 
possess some degree of androgenic activity in its own right, acting as a 
low affinity (Ki = 1 μM), weak partial agonist of the androgen receptor. However, 
its intrinsic activity at the receptor is almost completely negligible, and on account 
of that, due to competition for binding with full agonists like testosterone, it 
actually behaves much more like an antagonist there, and hence, like an anti-
androgen. However, its affinity for the receptor is very low, and for that reason, is 
unlikely to be of any significance under normal circumstances. In addition to its 
affinity for the androgen receptor, DHEA has also been found to bind to and 
activate the ER α and ER β estrogen receptors with Ki values of 1.1 μM and 0.5 
μM, respectively, and EC50 values of >1 μM and 200 nM, respectively. Though it 
was found to be a partial agonist of the ER α with a maximal efficacy of 30-70%, 
the concentrations required for this degree of activation make it unlikely that the 
activity of DHEA at this receptor is physiologically meaningful. Remarkably 
however, DHEA acts as a full agonist of the ER β with a maximal response similar 
to or actually slightly greater than that of estradiol, and its levels in circulation and 
local tissues in the human body are high enough to activate the receptor to the 
same degree as that seen with circulating estradiol levels at somewhat higher than 
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their maximal, non-ovulatory concentrations; indeed, when combined with 
estradiol with both at levels equivalent to those of their physiological 
concentrations, overall activation of the ER β was doubled. As such, it has been 
proposed that DHEA may be an important and potentially major 
endogenous estrogen in the body[58,59]. 
 Unlike the case of the androgen and estrogen receptors, DHEA does not bind 
to or activate the progesterone, glucocorticoid, or mineralocorticoid receptors.  
Other nuclear receptor targets of DHEA include the PPAR-α, PXR, and CAR. In 
addition, it has been found to directly act on several membrane receptors, including 
the NMDA receptor as a positive allosteric modulator, the GABAA receptor as 
a negative allosteric modulator, and the σ1 receptor as an agonist. It is these actions 
that have conferred the label of a "neurosteroid" upon DHEA[47]. Finally, DHEA is 
thought to regulate a handful of other proteins via indirect, genomic mechanisms, 
including the enzymes P4502C11 and11β-HSD1—the latter of which is essential 
for the biosynthesis of the glucocorticoids such as cortisol and has been suggested 
to be involved in the anti-glucocorticoid effects of DHEA—and 
the carrier IGFBP1. 
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MEASUREMENT  
 As almost all DHEA is derived from the adrenal glands, blood 
measurements of DHEA / DHEA-s are useful to detect excess adrenal activity as 
seen in adrenal cancer or hyperplasia, including certain forms of congenital adrenal 
hyperplasia. Women with polycystic ovary syndrome tend to have high DHEA. 
Serum DHEA concentration exhibits a circadian rhythm that reflects the secretion 
of corticotropin (ACTH); they also vary during the menstrual cycle, being higher 
during the luteal phase. In contrast, serum DHEA sulfate concentrations do not 
exhibit a circadian rhythm because the plasma half-life of DHEA sulfate is much 
longer. DHEA and DHEA sulfate are derived from 17-hydroxypregnenolone and 
17-hydroxyprogesterone. Their serum concentrations are, therefore, increased in 
conditions in which the concentration of these steroids is increased.                                                                                      
 
  Figure 15 - ENDOGENOUS PRODUCTION OF DHEA 
 56 
 
CHEMILUMINESCENCE IMMUNOASSAY: (CLIA) 
 CLIA is the one of the detection methods used in clinical laboratory. CLIA use 
chemiluminescent labels. Chemiluminescent molecules produce light when they 
are excited by chemical energy. Isoluminol and acridinium esters are the most 
commonly used as chemiluminescent labels. 
Advantages of CLIA: 
 Relatively quick. 
 Economical. 
 More sensitive compared to calorimetric method. 
 
             
 
 
DHEA-sulphate is estimated using CLIA method in this study. 
     Figure 16 – MEASUREMENT OF DHEAs BY CLIA METHOD 
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Table 3 - NORMAL RANGE OF DHEA-s 
 
 
AGE GROUP 
(yr) 
DHEA-s LEVEL (µg/dl) 
MALE FEMALE 
18-19 108 - 441 145 - 395 
20-29 280 - 640 65 - 380 
30-39 120 - 520 45 - 270 
40-49 95 - 530 32 - 240 
50-59 70 - 310 26 - 200 
60-69 42 - 290 13 - 130 
≥ 70 28 - 175 17 - 90 
 
                            
    Figure 17 – DHEA LEVELS WITH AGE 
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INCREASING ENDOGENOUS PRODUCTION 
 Regular exercise is known to increase DHEA production in the 
body. Calorie restriction has also been shown to increase DHEA in primates. Some 
theorize that the increase in endogenous DHEA brought about by calorie restriction 
is partially responsible for the longer life expectancy known to be associated with 
calorie restriction. 
 
ISOMERS 
 The term "dehydroepiandrosterone" is ambiguous chemically because it 
does not include the specific positions within epiandrosterone at which hydrogen 
atoms are missing. DHEA has a number of naturally occurring isomers that may 
have similar pharmacological effects. Some isomers of DHEA are 1-
dehydroepiandrosterone and 4-dehydroepiandrosterone. These isomers are also 
technically DHEA, since they are dehydroepiandrosterones in which hydrogens are 
removed from the epiandrosterone skeleton. 
 
EFFECTS AND USES 
 In women with adrenal insufficiency and the healthy elderly there is 
insufficient evidence to support the use of DHEA[19]. 
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STRENGTH 
 Evidence is inconclusive with regards to the effect of DHEA on strength in 
the elderly[50]. In middle-aged men, no statistically significant effect of DHEA 
supplementation on lean body mass, strength, or testosterone levels was found in a 
randomized placebo-controlled trial[55]. One large (100 subjects) trial found no 
effect on strength following DHEA supplementation in the elderly group in the 
study. However, a small study suggested DHEA supplementation was associated 
with increases in free (but not total) testosterone levels. In postmenopausal women, 
within a randomized placebo-controlled trial, no statistically significant effect of 
DHEA supplementation on muscle strength was seen during a 12 week combined 
endurance and weight training program[56]. 
 
MEMORY 
 DHEA supplementation has not been found to be useful for memory 
function in normal middle aged or older adults[51,73]. It has been studied as a 
treatment for Alzheimer's disease, but there is no evidence that it is effective. 
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FEMALE REPRODUCTIVE HEALTH 
 Since 2000, DHEA supplementation has been used in reproductive medicine 
in combination with gonadotropins as a way to treat female infertility. 
 
CARDIOVASCULAR DISEASE AND RISK OF DEATH 
 A review in 2003 found the then-extant evidence sufficient to suggest that 
low serum levels of DHEA-s may be associated with coronary heart disease in 
men, but insufficient to determine whether DHEA supplementation would have 
any cardiovascular benefit. A 2001 study found that a higher level 
of endogenous DHEA, as determined by a single measurement, correlated with a 
lower risk of death or cardiovascular disease[61,64,70]. However, a 2006 study found 
no correlation between DHEA levels and risk of cardiovascular disease or death in 
men. A 2007 study found that DHEA restored oxidative balance in 
diabetic patients, reducing tissue levels of pentosidine—a biomarker for advanced 
glycation endproducts.  
 
LUPUS 
There is some evidence of short term benefit in those with systemic lupus 
erythematosus but little evidence of long term benefit or safety[69].  
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SAFETY 
 DHEA is produced naturally in the human body, but the long term effects of 
its use are largely unknown. In the short term, several studies have noted few 
adverse effects. In a study by Chang et al., DHEA was administered at a dose of 
200 mg/day for 24 weeks with slight androgenic effects noted. Another study 
utilized a dose up to 400 mg/day for 8 weeks with few adverse events reported. A 
longer term study followed patients dosed with 50 mg of DHEA for 12 months 
with the number and severity of side effects reported to be small. Another study 
delivered a dose of 50 mg of DHEA for 10 months with no serious adverse events 
reported.  
 As a hormone precursor, there has been a smattering of reports of side 
effects possibly caused by the hormone metabolites of DHEA. It is not known 
whether DHEA is safe for long-term use. Some researchers believe DHEA 
supplements might actually raise the risk of breast cancer, prostate cancer, heart 
disease, diabetes, and stroke. DHEA may stimulate tumor growth in types of 
cancer that are sensitive to hormones, such as some types of breast, uterine, and 
prostate cancer. DHEA may increase prostate swelling in men with benign 
prostatic hyperplasia (BPH), an enlarged prostate gland.  
 DHEA is a steroid hormone. High doses may cause aggressiveness, 
irritability, trouble sleeping, and the growth of body or facial hair on women. It 
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also may stop menstruation and lower the levels of HDL ("good" cholesterol), 
which could raise the risk of heart disease. Other reported side effects include acne, 
heart rhythm problems, liver problems, hair loss (from the scalp), and oily skin. It 
may also alter the body's regulation of blood sugar[60].  
 DHEA should not be used with tamoxifen, as it may promote tamoxifen 
resistance. Patients on hormone replacement therapy may have more estrogen-
related side effects when taking DHEA. This supplement may also interfere with 
other medicines, and potential interactions between it and drugs and herbs should 
be considered.  
 DHEA is possibly unsafe for individuals experiencing the following 
conditions: pregnancy and breast-feeding, hormone sensitive conditions, liver 
problems, diabetes, depression or mood disorders, polycystic ovarian 
syndrome (PCOS) or cholesterol problems. 
 
RESEARCH 
CANCER 
 Some in vitro studies have found DHEA to have both anti-proliferative 
and apoptotic effect on cancer cell lines. The clinical significance of these findings, 
if any, is unknown. Higher levels of DHEA and other endogenous sex hormones 
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are strongly associated with an increased risk of developing breast cancer in 
both pre and postmenopausal women 
 
LEGALITY  
 DHEA is legal to be sold in the United States as a dietary supplement. It is 
currently grandfathered in as an "Old Dietary Ingredient" being on sale prior to 
1994. DHEA is specifically exempted from the Anabolic Steroid Control Act of 
1990 and 2004. It is banned from use in athletic competition. DHEA and DHEA-s 
are readily available in the United States, where they are marketed as over-the-
counter dietary supplements. 
 
DHEA-s AND LONGEVITY: NEW CLUES FOR AN OLD FRIEND?  
During the past five decades, a myriad of animal experiments has suggested 
that DHEA is a multifunctional hormone with immunoenhancing, anti-diabetic, 
antiobesity, anti-cancer, neurotropic, memory-enhancing, and anti-aging effects. 
Because a backdrop of these studies was conducted in rodents with little or no 
detectable circulating DHEA, it may be viewed as a pharmacological model with a 
naive environment that is devoid of endogenous DHEA. 
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DHEA modulates endothelial function, reduces inflammation, improves 
insulin sensitivity, blood flow, cellular immunity, body composition, bone 
metabolism, sexual function, physical strength, provides neuroprotection, improves 
cognitive function, and memory enhancement. DHEA possesses ‘pleiotropic’ 
effects and reduced levels of DHEA and DHEA-s may be associated with a host of 
pathologies[67]. 
         Figure 18 – DHEA – PLEOTROPIC EFFECTS 
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 The secretion of DHEA by the human adrenal gland exhibits a pulsatile 
pattern with increasing frequency and amplitude at night. This pattern of DHEA 
synthesis and secretion by the zona reticularis is, in large measure, mediated by 
corticotrophin (ACTH) but without the feedback regulatory function. With aging, 
the progressive blunting of ACTH mediates pulsatile activities, particularly the 
nocturnal amplification of DHEA, without affecting the pulsatile rhythm of 
cortisol. Although the decline of DHEA-s levels persists into advanced age with a 
sexually dimorphic pattern, in contrast, cortisol levels in men and women show a 
parallel linear increase with aging. The age-related decline in DHEA-s shows 
marked individual differences with a wide range of values and is under partial 
hereditary control. It has been suggested that DHEA-s may be a measurable 
component of the individuality of the aging process itself. 
 In human aging, the reduction of adrenal androgen secretion is accompanied 
by a host of neuroendocrine–metabolic dysfunctions that include decline in the 
growth hormone-insulin-like growth factor I (GH-IGF-I) system, thyroid function, 
immune competence, fragmentation of sleep and neuronal loss. DHEA-s has a 
strong interrelation with functional activities observed in the oldest men in a study 
conducted by Ravaglia et al[60]. 
 DHEA-s has also been shown to induce peroxisome gene expression 
mediated through the activation of peroxisome proliferator activated receptor-α 
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(PPAR-α), as reported by Peters et al. DHEA and α-Adiol are both inactive in this 
regard, suggesting the importance of 3β-sulfate that may be required for structural 
confirmation for PPAR-α. Thus, DHEA-s may serve as an important endogenous 
regulator of hepatic PPAR-α mediated pathways thereby maintain lipid 
homeostasis and prevent decline in cellular PPAR-α expression in normal aging. 
The administration of DHEA-s to aging animals elicits a number of biologic 
changes that are mediated through a process involving PPAR-α activation with 
reversal of the dysregulated cytokines, particularly IL-6. In humans, James et al. 
and Straub et al. have provided evidence that serum levels of IL-6 increase with 
age and that serum DHEA-s levels are negatively correlated with serum IL-6 
concentrations in both aging men and women[14]. The maximal effective dose of 
DHEA is in the range for immunomodulation. Thus, the increase in IL-6 
production during the process of aging might be related to diminished DHEA-s 
secretion, which, in turn, may be a significant cofactor for the manifestation of 
inflammatory and age-related diseases, including bone loss. 
 
INFLAMMAGING AND ANTI-INFLAMMAGING:  
 ‘Inflamm-aging’ is the portmanteau word for inflammation and aging. A 
global reduction in the capacity to cope with a variety of stressors and a 
concomitant progressive increase in pro-inflammatory status are major 
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characteristics of the aging process. This phenomenon, which we will refer to as 
"inflamm-aging," is provoked by a continuous antigenic load and stress. A large 
part of the aging phenotype, including immunosenescence, is explained by an 
imbalance between inflammatory and anti-inflammatory networks, which results in 
the low grade chronic pro-inflammatory status. Within this perspective, healthy 
aging and longevity are likely the result, not only of a lower propensity to mount 
inflammatory responses but also of efficient anti-inflammatory networks, which in 
normal aging fail to fully neutralize the inflammatory processes consequent to the 
lifelong antigenic burden and exposure to damaging agents. Such a global 
imbalance can be a major driving force for frailty and common age-related 
pathologies. 
     
Figure 19 - INFLAMMAGING 
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The rate of reaching the threshold of pro-inflammatory status over which 
diseases/disabilities ensue and the individual capacity to cope with and adapt to 
stressors are assumed to be complex traits with a genetic component. The 
persistence of inflammatory stimuli over time represents the biologic background 
favoring the susceptibility to age-related diseases/disabilities. To conclude, the 
beneficial effects of inflammation devoted to the neutralization of harmful agents 
early in life and in adulthood become detrimental late in life.  
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MATERIALS AND METHODS 
Study Centre: Geriatric ward (Male & Female) in Rajiv Gandhi Government 
General Hospital, Madras Medical College, Chennai. 
Ethical Committee approval: Ethical Committee clearance obtained from 
Institutional Ethics Committee of Madras Medical College held on 03-06-2014. 
Study Design: Hospital based Observational study. 
Duration of the Study: 3 months. (from June 2014 to August 2014) 
Sample Size: 100 patients. 
Inclusion Criteria: 
 Subjects - 65 years of age or above. 
 Those who are willing to participate & co-operative for the study. 
Exclusion Criteria:  
 Patients who are not willing to consent.  
 Critically ill patients who are not able to participate.  
 H/O use of DHEA, androgen or estrogen in the preceding year. 
 H/O Adrenal insufficiency / tumour. 
 H/O  Breast cancer / Prostate cancer. 
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Details of the study: 
 Patients were selected as per the above mentioned inclusion and exclusion 
criteria. Relevant history was obtained. Anthropometric evaluation was done. 
Fried’s criteria was employed to assess the frailty phenotype. It comprises of 5 
components. They are- 
1) Self-reported weight loss. 
2) Grip strength measured by hand dynamometer. 
3) Sense of exhaustion – self reported. 
4) 15 ft walking speed. 
5) Physical activity assessed by Minnesota Leisure time activity questionnaire. 
(short version) 
Patients were categorized into 3 groups based on the number of frailty components.  
 FRAIL ( ≥ 3 characteristics) 
 INTERMEDIATE FRAIL (1-2 characteristics)  
 NON-FRAIL (no characteristic) 
33 frail, 34 intermediate frail and 33 non-frail patients were selected by Stratified 
random sampling method. Blood samples of patients from each group were 
collected and serum DHEA-s level was estimated. (using CLIA method) 
Informed consent was obtained from all study participants.  
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Table 4 - FRIED’S CRITERIA   
CHARACTERISTICS CUT OFFS 
1) Weight loss 
 
Baseline: 
Lost > 10 pounds unintentionally in last 
year (5% of previous year’s body 
weight) 
 
2) Exhaustion 
    CES-D 
 
Self report of either of: 
 
i) felt that everything I did was an effort 
in the last week 
ii) could not get going in the last week 
3) Low Physical Activity 
    Minnesota LTA questionnaire 
 
Women: Kcal/wk < 270 on activity scale 
 
Men: Kcal/wk < 383 on activity scale 
4) Slowness 
    Walking 15 ft (4.57m) at usual pace 
 
Women: 
time ≥ 7 s for height ≤ 159 cm 
time ≥ 6 s for height > 159 cm 
 
Men: 
time ≥ 7 s for height ≤  173 cm 
time ≥ 6 s for height > 173 cm 
5) Weakness 
    Grip strength 
 
Women:  
≤ 17 kg for BMI ≤  23 
≤ 17.3 kg for BMI 23.1 - 26 
≤ 18 kg for BMI 26.1 - 29 
≤ 21 kg for BMI > 29 
 
Men: 
≤ 29 kg for BMI <= 24 
≤ 30 kg for BMI 24.1 - 26 
≤ 30 kg for BMI 26.1 - 28 
≤ 32 kg for BMI > 28 
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Figure 20 - HAND DYNAMOMETER FOR ASSESSMENT OF  
GRIP STRENGTH 
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Table 5 - SHORT VERSION OF MINNESOTA LEISURE TIME PHYSICAL 
ACTIVITY QUESTIONNAIRE 
 
ACTIVITIES PERFORMED 
(YES/NO) 
TIME 
(Min/Week) 
CALCULATED 
(Kcal/week) 
Walking for pleasure    
Walking to & from work    
Using stairs when 
elevator is available 
   
Back packing    
Mountain climbing    
Bicycling    
Dancing    
Home exercise    
Health club    
Jogging    
Running    
Weight lifting    
Lawn & garden activities    
Sports    
Miscellaneous    
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Statistical analysis: 
 
Descriptive statistics (mean ± standard deviation or count/proportion) were 
calculated for each study variable. 
A contingency table was created to summarise variation in the frequency of 
frailty categories (0 = Non-Frail, 1–2 = Intermediate Frail and 3–5 = Frail) relative 
to DHEA-s quartiles (15.0–27.4, 27.5–46.4, 46.5–78.4 and ≥ 78.5 μg/dL). The 
Pearson χ2 test was applied to assess the statistical significance of the relationship 
between frailty categories and DHEA-s levels. 
The potential that either an observed association or lack of association 
between frailty and DHEA-s could be due to confounding by other subject 
characteristics was evaluated. The Pearson χ2 test was applied to investigate 
relationships between frailty and these other characteristics age (65–74, 75–84, ≥ 
85), gender and body mass index ( ≤ 24, 24-29, ≥ 29) 
Multivariable ordinal logistic regression was used to establish the 
relationship between frailty and DHEA-s while controlling for the potential 
confounding effects of other subject characteristics. Frailty was the dependent 
variable in the modelling process. DHEA-s was the primary independent 
variable. 
Analyses were performed using the XLSTAT 2014 software package. A 5% 
threshold was used for declaring a statistical significance in all tests. 
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RESULTS 
Of the 100 study subjects, 53 were male and 47 were female. The mean age 
of the study population was 77.12 yr (SD=± 6.79 yr). The mean DHEA-s level was 
49.55 ± 24.97 µg/dl. Descriptive statistics of the study is tabulated. (Table 6) 
CHARACTERISTICS OF STUDY SUBJECTS MEAN ± SD (or) COUNTS/% 
Gender 
   Male 
   Female 
53/53% 
47/47% 
Age (yr) 77.12 ± 6.79 
BMI (kg/m²) 25.08 ± 3.10 
DHEA-s (μg/dL) 49.55 ± 24.97 
Frailty assessment components 
   15-ft walking speed (m/s) 
   Physical activity (kcal/wk) 
   Handgrip strength (kg) 
   Weight loss 
   Exhaustion 
 
0.70 ± 0.18 
1254 ± 1092 
14.82 ± 9.35 
13/13% 
33/33% 
Number of frailty components 
   0 (non-frail) 
   1 (intermediate) 
   2 (intermediate) 
   3 (frail) 
   4 (frail) 
   5 (frail) 
 
33/33% 
17/17% 
17/17% 
11/11% 
12/12% 
10/10% 
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Of the 34 intermediate frail subjects, 17 had one frailty component and 17 
had two frailty components. In the frail category, 11 had 3 frail characteristics, 12 
had 4 characteristics and 10 had all 5 characteristics. 
  
33
1717
11
12
10
0 component
1 component
2 components
3 components
4 components
5 components
PREFRAIL
NON-FRAIL
Chart 1 - DISTRIBUTION OF NUMBER OF FRAILTY COMPONENTS
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 Reduced grip strength is the common frail characteristic observed among the 
pre-frail subjects, followed by slow gait speed. Reduced grip strength & low 
physical activity were invariably noted in the frail group followed by slow gait 
speed & exhaustion. 
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PARAMETER 
 
NON-FRAIL 
 
INTERMEDIATE 
 
FRAIL 
No of subjects (n) 33 34 33 
Age (yr) 74.85 ± 7.12 76.35 ± 6.03 80.18 ± 6.20 
Height (cm) 159.48 ± 7.99 154.41 ± 6.90 151.61 ± 5.56 
Weight (kg) 62.48 ± 9.34 61.43 ± 7.04 57.41 ± 9.58 
BMI (kg/m²) 24.48 ± 2.37 25.79 ± 2.73 24.95 ± 3.98 
Gait speed (m/s) 0.84 ± 0.08 0.74 ± 0.17 0.53 ± 0.14 
Grip strength (kg) 25.30 ± 6.37 11.85 ± 6.21 7.39 ± 3.44 
DHEA-s level (µg/dl) 64.42 ± 22.54 47.99 ± 22.12 36.28 ± 21.72 
 
 The mean ± SD of the study variables of each category is tabulated. The 
frailty phenotype increased with advancing age. The mean DHEA-s level was the 
lowest among the frail group. 
  
Table 7 – DESCRIPTIVE STATISTICS OF FRAILTY CATEGORIES 
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The mean ± SD of study variables of each group (according to gender) is 
tabulated. The mean DHEA-s level did not vary much across the sexes. 
 
PARAMETER 
 
NON-FRAIL 
 
INTERMEDIATE 
 
FRAIL 
MALE FEMALE MALE FEMALE MALE FEMALE 
No of subjects (n) 18 15 18 16 17 16 
Age (yr) 75 ± 7.20 74.67 ± 6.92 76.56 ± 6.46 76.13 ± 6.02 80.41 ± 6.14 79.94 ± 6.61 
Height (cm) 163.72 ± 6.65 154.40 ± 5.57 159.78 ± 3.28 148.38 ± 4.86 155.24 ± 4.16 147.75 ± 4.01 
Weight (kg) 66.83 ± 8.13 57.27 ± 7.03 64.39 ± 4.34 58.09 ± 7.93 60.03 ± 9.39 54.63 ± 9.70 
BMI (kg/m²) 24.90 ± 2.37 23.96 ± 2.08 25.26 ± 2.08 26.38 ± 3.25 24.91 ± 3.78 25.01 ± 4.36 
Gait speed (m/s) 0.89 ± 0.06 0.78 ± 0.05 0.78 ± 0.19 0.69 ± 0.12 0.57 ± 0.17 0.50 ± 0.08 
Grip strength (kg) 29.5 ± 4.31 20.27 ± 4.50 11.67 ± 5.49 12.06 ± 6.95 9.29 ± 2.85 5.38 ± 2.80 
DHEA-s level 
(µg/dl) 
65.93 ± 21.13 62.61 ± 23.82 49.21 ± 22.59 46.61 ± 22.17 35.24 ± 23.20 37.38 ± 23.34 
Table 8 - DESCRIPTIVE STATISTICS OF FRAILTY        
CATEGORIES (GENDER BASED) 
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 The mean age of the frail group was 80.18 yrs and that of the non-frail group 
was 74.85 yrs. The ANOVA test revealed a statistical significance between the 
mean age of the frailty categories. (p < 0.0001) 
  
Table 9 - MEAN AGE OF STUDY GROUPS 
AGE NON-FRAIL INTERMEDIATE FRAIL p-VALUE 
MEAN (yr) 74.85 76.35 80.18 
< 0.0001* 
SD (yr) 7.12 6.03 6.20 
*statistically significant. 
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 32% (17) of males were frail compared to 34% (16) females. Similar 
percents were noted among non-frail males and females. The test did not reveal 
any statistical significance between both sexes with regards to frailty category. 
(p=0.97) 
 
Table 10 - SEX DISTRIBUTION AMONG STUDY GROUPS 
GENDER NON-FRAIL INTERMEDIATE FRAIL TOTAL p-value 
MALE 18 18 17 53 
0.97 FEMALE 15 16 16 47 
TOTAL 33 34 33 100 
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There was no statistical significance between the mean BMI of the study 
groups. (p = 0.99) 
 
Table 11 - MEAN  BMI  OF  STUDY  GROUPS 
BMI NON-FRAIL INTERMEDIATE FRAIL p-VALUE 
MEAN (kg/m²) 24.48 25.79 24.95 
0.99 
SD (kg/m²) 2.37 2.73 3.98 
 
23.5 24 24.5 25 25.5 26
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INTERMEDIATE
FRAIL
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Chart 5 - MEAN  BMI  OF  STUDY  GROUPS 
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 The mean grip strength of non-frail group was 25.3 kg whereas it was as low 
as 7.39 kg among frail group. There was a statistical difference between the mean 
grip strength of the frailty categories. (p < 0.0001) 
 
Table 12 - MEAN  HANDGRIP  STRENGTH  OF  STUDY  GROUPS 
GRIP STRENGTH NON-FRAIL INTERMEDIATE FRAIL p-VALUE 
MEAN (kg) 25.3 11.85 7.39 
< 0.0001* 
SD (kg) 6.37 6.21 3.44 
*statistically significant.  
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 The mean gait speed of the non-frail group was 0.84 m/s and 0.53 m/s for 
the frail group. There was a statistical difference between the mean gait speed of 
the frailty categories. (p < 0.0002) 
 
Table 13 - MEAN  GAIT  SPEED  OF  STUDY  GROUPS 
GAIT SPEED NON-FRAIL INTERMEDIATE FRAIL p-VALUE 
MEAN (m/s) 0.84 0.74 0.53 
< 0.0002* 
SD (m/s) 0.08 0.17 0.14 
*statistically significant. 
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 The DHEA-s level decreased as the magnitude of frailty increased. The 
mean level of DHEA-s of the non-frail group was 64.42 µg/dl and 36.28 µg/dl for 
the frail group. There was a statistical difference between the mean DHEA-s level 
of the frailty categories. (p < 0.002) 
 
Table 14 - MEAN  DHEA-s  LEVEL  OF  STUDY  GROUPS 
DHEA-s LEVEL NON-FRAIL INTERMEDIATE FRAIL p-VALUE 
MEAN (µg/dl) 64.42 47.99 36.28 
< 0.002* 
SD (µg/dl) 22.54 22.12 21.72 
*statistically significant. 
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PARAMETER 
 
OVERALL 
 
MALE 
 
FEMALE 
No of subjects (n) 100 53 47 
Age (yr) 77.12 ± 6.79 77.26 ± 6.88 76.96 ± 6.76 
Height (cm) 155.16 ± 7.50 159.66 ± 5.95 150.09 ± 5.60 
Weight (kg) 60.45 ± 8.82 63.82 ± 7.93 56.65 ± 8.28 
BMI (kg/m²) 25.08 ± 2.37 25.02 ± 2.77 25.14 ± 3.46 
Gait speed (m/s) 0.70 ± 0.18 0.75 ± 0.20 0.65 ± 0.15 
Grip strength (kg) 14.82 ± 9.35 16.96 ± 10.09 12.40 ± 7.86 
DHEA-s level (µg/dl) 49.55 ± 24.97 50.41 ± 25.25 48.57 ± 24.89 
 
 The mean ± SD of  the study variables is tabulated according to gender. 
The gait speed & grip strength varied between the sexes but the DHEA-s level did 
not vary. 
  
Table 15 - DESCRIPTIVE STATISTICS BASED ON GENDER 
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 The mean grip strength of males was 16.96 kg whereas it was 12.4 kg 
among females. There was a statistically significant difference between the mean 
grip strength of both sexes. (p < 0.004) 
 
Table 16 - MEAN GRIP STRENGTH OF SEXES 
GRIP STRENGTH MALE FEMALE p-VALUE 
MEAN (kg) 16.96 12.4 
< 0.004* 
SD (kg) 10.09 7.86 
*statistically significant. 
0
2
4
6
8
10
12
14
16
18
MALE FEMALE
16.96
12.4
MEAN GRIP STRENGTH (kg)
Chart 9 - MEAN GRIP STRENGTH OF SEXES
G
RI
P 
ST
RE
N
G
TH
 (k
g)
 88 
 
 
 The mean gait speed of males was 0.75 m/s and 0.65 m/s for females . There 
was a statistically significant difference between the mean gait speed of both sexes. 
(p < 0.04) 
 
Table 17 - MEAN GAIT SPEED OF SEXES 
GAIT SPEED MALE FEMALE p-VALUE 
MEAN (m/s) 0.75 0.65 
< 0.04* 
SD (m/s) 0.20 0.15 
*statistically significant. 
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 The mean DHEA-s level of males was 50.41 µg/dl and 48.57 µg/dl for 
females. There was no statistical difference between the mean DHEA-s level of 
both sexes. (p = 0.93) 
 
Table 18 - MEAN  DHEA-s  LEVEL  OF SEXES 
DHEA-s LEVEL MALE FEMALE p-VALUE 
MEAN (µg/dl) 50.41 48.57 
0.93 
SD (µg/dl) 25.25 24.89 
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DHEA-s level & Frailty categories: 
A cross-tabulation of frailty categories by DHEA-s quartiles suggested a 
signiﬁcant association between the two variables (p < 0.0004). 16% of subjects in 
the highest quartile of DHEA-s values had zero frailty components. This 
percentage consistently decreased (16% vs 7% vs 4%) as the frailty phenotype 
increased. Conversely, the percentage of subjects classiﬁed as frail increased from 
the highest quartile to the lowest. (4% vs 5% vs 7% vs 17%).  
 
Table 19 - DHEA-s LEVEL & FRAILTY CATEGORIES 
DHEA-s 
quartile 
(µg/dl) 
NON-FRAIL INTERMEDIATE FRAIL 
TOTAL p-value 
MALE FEMALE MALE FEMALE MALE FEMALE 
15.0 - 27.4 1 2 3 3 9 8 26 
0.0004* 
27.5 - 46.4 4 2 6 5 3 4 24 
46.5 - 78.4 5 3 5 5 3 2 23 
≥ 78.5 8 8 4 3 2 2 27 
TOTAL 
18 15 18 16 17 16 
100 
33 34 33 
*statistically significant. 
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This chart depicts the frequency distribution based on DHEA-s quartiles & 
Frailty categories. It is obvious from the chart that the frequencies of non-frail with 
high DHEA-s level and frail with low DHEA-s level are high portraying an inverse 
association between the two variables. 
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Age group & Frailty categories: 
 
Table 20 - AGE GROUP & FRAILTY CATEGORIES 
AGE 
(yr) 
NON-FRAIL INTERMEDIATE FRAIL 
TOTAL p-value 
MALE FEMALE MALE FEMALE MALE FEMALE 
65-74 9 8 6 6 4 4 37 
0.03* 
75-84 7 6 10 8 7 7 45 
≥85 2 1 2 2 6 5 18 
TOTAL 
18 15 18 16 17 16 
100 
33 34 33 
*statistically significant. 
  
In the ≥ 85 age group,11 out of 18 (61%) were frail compared to 3 out of 18 
(17%) who were non-frail, whereas in the 65-74 age group, only 8 out of 37 (22%) 
were frail compared to 17 out of 37 (46%) who were non-frail. The Chi-square test 
denotes a significant difference between the two variables. (p < 0.03)  
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 With increase in age, the transition from non-frail to frail becomes evident. 
The frequencies of non-frail are highest and lowest among the young old (65-74 
yr) and oldest old ( ≥ 85 yr) respectively. 
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BMI and Frailty categories: 
 
Table 21 - BMI AND FRAILTY CATEGORIES 
BMI 
(kg/m²) 
NON-FRAIL INTERMEDIATE FRAIL 
TOTAL p-value 
MALE FEMALE MALE FEMALE MALE FEMALE 
≤ 24 7 6 6 5 7 7 38 
0.36 
24 - 29 8 8 9 8 6 4 43 
≥ 29 3 1 3 3 4 5 19 
TOTAL 
18 15 18 16 17 16 
100 
33 34 33 
 
There was no significant association between BMI and frailty categories. (p=0.36) 
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Though there was no significant association between BMI & frailty 
categories, there was a significant DHEAs–BMI interaction that affected the 
former’s relation with frailty. The modelling process revealed that the magnitude 
of the association between frailty and DHEA-s was dependent on BMI. 
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The relationship between higher levels of frailty decreased relative to higher 
levels of DHEA-s, but the magnitude of decrease was larger at lower BMI values 
and smaller at higher BMI values.  
The relationship between being more frail decreased by a factor of 0.18 
(95% CI 1.036, 1.379; p = 0.02) for every one unit increase in the DHEA-s level 
when BMI was ≤ 24 kg/m² (the lowest BMI quartile cut-off). In contrast, being 
more frail decreased only by a factor of 0.003 (95% CI 0.953, 1.055; p = 0.92) for 
every one unit increase in the DHEA-s level when BMI was ≥ 29 kg/m² (the 
highest BMI quartile cut-off). Having an intermediate BMI (24-29 kg/m²)  resulted 
in an intermediate change by a factor of 0.08 (95% CI 0.797, 3.658; p = 0.05).  
When the data were simultaneously cross-classified by frailty category, 
DHEA-s quartile and BMI level, the modifying effect of BMI on the association 
between frailty and DHEAS was evident. The graphical representation of the 
association suggested that there might be a threshold such that the inverse 
relationship between frailty and DHEA-s holds good for BMI values < 29 kg/m² 
and was weaker or absent for BMI values ≥ 29 kg/m².  
The inverse relationship between DHEA-s and higher levels of frailty was 
strongest when BMI was < 29 kg/m² (OR =1.09, 95% CI 1.049, 1.139, p = 0.0001) 
and substantially weaker (OR = 0.82, 95% CI 0.953, 1.055; p = 0.92) when BMI 
exceeded 29 kg/m². 
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DISCUSSION 
 In this cross-sectional study of 100 elder men and women, we found that 
age, DHEA-s level and  DHEAs-BMI interaction were associated with higher 
frailty categorization. We observed that an inverse association exists between 
DHEA-s level & frailty categories and the frailty phenotype increased with 
advancing age.  
 In a study conducted by Voznesensky et al[1], there were significant 
differences between categories of frailty across age (p < 0.0001), gender (p = 
0.0005) and by DHEA-s levels (p < 0.0001). Our study noted significant difference 
across age (p = 0.03) and by DHEA-s levels (p = 0.0004) but did not observe any 
significant difference between the sexes (p=0.97). The mean age & DHEA-s level 
of the above study are 74.6 ±7.7 yrs & 59.2 ± 44.6 μg/dl respectively while the 
corresponding values for our study read 77.12 ± 6.79 yrs & 49.55 ± 24.97 μg/dl.  
Results of ordinal logistic regression model of both studies were comparable. With 
frailty as a dependent measure, both studies inferred that age, DHEA-s and 
interaction between DHEAs-BMI were predictive of more frailty characteristics. 
 In a study conducted by Leng et al[14], DHEA-s levels were lower among 
frail individual (p < 0.02). In another study conducted by Abbasi et al, men in the 
highest quartile of serum DHEA-s level were younger & more fit compared with 
those with a serum DHEA-s level in the lowest quartile. However no such 
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differences were identified between the women in the highest and the lowest 
quartiles of serum DHEA-s level. 
In a study conducted by Paola Forti et al, low DHEA-s levels were 
associated with high degrees of self-rated disability[57]. In another study conducted 
by Berkman et al[15], high functioning among elders was found with those who 
have higher levels of DHEA-s. 
In contrast, a cross-sectional study of 60 heart failure patients conducted by 
Boxer et al[18], failed to find an association between frailty and DHEA-s level. 
In a study conducted by Lise Mazat et al., higher DHEA-s level was 
observed in subjects who had better mobility and physical performance. DHEA-s 
levels decreased significantly with increasing age in both sexes. 
Several previous studies examined the relationship between DHEA-s and 
BMI with conflicting findings. Barrett-Connor and Ferrara[20], in a study of post-
menopausal women, found DHEA-s levels to be directly associated with central 
obesity. Conversely, DHEA-s levels are inversely related with abdominal obesity 
or BMI >30 kg/m² in middle age and elderly men. Abbasi et al[17]., found DHEA-s 
to be positively correlated to BMI in women 60–80 years old, but not in men. Our 
study found a statistical significance between BMI and DHEA-s level as suggested 
by a p value of < 0.0001. 
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While the studies on the relationship between obesity and DHEA levels have 
been conflicting, frailty has been linked to higher BMI in a syndrome known as 
‘sarcopenic obesity’[27]. 
The association between frailty and a higher BMI may explain the 
attenuation of the association between DHEA-s and frailty at higher BMI. The 
mechanism may be direct. Sarcopenic obesity is associated with a decrease in 
strength and a decrease in mobility, two factors associated with frailty. The 
mechanism may also be indirect, as obesity is related to several biochemical 
markers associated with frailty, including elevated levels of inflammatory markers 
such as IL-6 and C-reactive protein and lower anti-oxidant capacity[28]. 
Blaum et al[29]., evaluated the association between obesity and frailty in 
elderly women and found that overweight (BMI 25–29.99 kg/m²) individuals were 
more likely to be classified as intermediate frail and obese individuals (BMI > 30 
kg/m²) were more likely to be frail. We did not find a direct association between 
BMI and frailty, but did find an interaction between BMI and DHEA-s that was 
associated with frailty status. DHEA-s exhibited a protective effect against frailty 
in those with normal or overweight BMI, but the effect was lost in those with BMI 
> 30 kg/m² and may be explained by the biochemical markers associated with 
frailty, lower antioxidant capacity or the increased disabilities related to sarcopenic 
obesity. 
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In a study conducted by Fried LP et al[6]., frailty and age are found to be 
associated, with its incidence increasing from 3.2% of individuals aged 65–70 yrs 
to 25.7% of individuals aged 85–89 yrs. Our study too observed a significant 
association between the two variables (p < 0.03). 
We found no gender interactions in the association between frailty and 
DHEA-s (p=0.97). Differences in DHEA-s levels between sexes have been 
described by Orentreich N et al[9]. Further, studies by Schaap LA et al[30]., have 
found an association between DHEA-s levels and physical performance in men, 
but not in women. While we found an association between frailty and DHEA-s 
levels, the association did not differ by gender. 
 In a study conducted by Ravaglia et al[60]., men with the highest functioning 
levels had the highest DHEA-s levels (P < 0.03). It suggested that DHEA-s levels 
may influence and/or be influenced by several endocrine and metabolic features of 
the  oldest-old people, depending on the sexual steroid milieu. A favorable role for 
DHEA-s in successful aging is proposed. 
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LIMITATIONS OF THE STUDY 
 The sample size is small (100 subjects).  
 Whether the association between frailty and DHEA-s is due to similar 
conditions resulting in lower DHEA-s levels and more susceptibility to 
frailty or whether lower DHEA-s levels have an impact on increasing frailty 
cannot be addressed by this cross-sectional analysis. 
 It does not address whether interventions to improve DHEA-s levels or 
modification in BMI will impact frailty status.  
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                                    CONCLUSION 
 The role of DHEA in frailty is uncertain, although low DHEA-s levels have 
been associated with increased rates of morbidity and mortality. 
 In this cross-sectional analysis of 100 elder men and women, an inverse 
association was observed between the frailty categories and DHEA-s level. 
Higher DHEA-s levels were associated with fewer frailty characteristics. 
 However, a BMI > 29 kg/m² attenuated the association found between 
DHEA-s level and frailty. 
 With advancing age, the frailty phenotype increased. 
 No gender interaction was observed in the association between frailty and 
DHEA-s level. 
 Further research will need to be done to ascertain whether the association is 
due to similar conditions resulting in lower DHEA-s levels and more 
susceptibility to frailty or whether lower DHEA-s levels have an impact on 
increasing frailty. 
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PROFORMA 
 
A STUDY ON THE ASSOCIATION BETWEEN 
DEHYDROEPIANDROSTERONE AND FRAILTY IN ELDERLY 
 
NAME:      AGE: 
SEX:       OP / IP NO.: 
ADDRESS:      DATE: 
 
Relevant History: H/O weight loss (10 lb in the past 1 year) 
   H/O exhaustion 
   H/O decrease in physical activity / grip strength / walking speed  
 
Past History: H/O Diabetes Mellitus / Systemic Hypertension 
   H/O Adrenal tumour / insufficiency 
   H/O Prostate cancer 
   H/O Breast cancer 
 
Drug History: DHEA / Estrogen / Androgen use in the preceding year 
 
Anthropometry: Height-  Weight-  BMI- 
 
 
  
FRAILTY ASSESSMENT COMPONENTS: (FRIED’S CRITERIA) 
 
 15 ft walking speed (in seconds): 
 
 Physical activity  (by Minnesota LTA questionnaire in kcal/wk): 
 
 Handgrip strength (by Hand Dynamometer in kg):  
 
 Weight loss (10 lb in the past 1 year): YES / NO 
 
 Exhaustion: YES / NO 
 
 
 
 
FRAILTY PHENOTYPE:  
 
 
  NON-FRAIL (0 characteristic) 
 
  INTERMEDIATE (1-2 characteristics) 
 
  FRAIL ( ≥ 3 characteristics) 
 
 
 
 
SERUM  DHEA-s  LEVEL (μg/dl): 
 
 
 
  
INFORMATION SHEET 
 
 
TITLE: A STUDY ON THE ASSOCIATION BETWEEN 
DEHYDROEPIANDROSTERONE AND FRAILTY IN ELDERLY 
 
NAME OF THE INVESTIGATOR: Dr. P.ARAVIND BABU 
STUDY CENTRE: Rajiv Gandhi Government General Hospital, Chennai.   
NAME OF THE PARTICIPANT:   AGE:  SEX: 
PURPOSE OF THE STUDY: To evaluate the association between 
dehydroepiandrosterone (DHEA) and frailty in the elder population. 
STUDY DESIGN: Observational study 
STUDY PROCEDURE: We are selecting cases as per Fried’s criteria and if you 
are found eligible, we may be using your blood sample (2 ml – only once)  to 
measure serum DHEA which in any way does not affect your final report or 
management. 
POSSIBLE RISKS: No possible risks by means of this study.  
POSSIBLE BENEFITS: If this study confirms the association, therapeutic 
intervention by means of supplementation with DHEA can be considered. 
CONFIDENTIALITY OF THE INFORMATION OBTAINED FROM THE 
PATIENT: The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
DECISION TO PARTICIPATE IN THE STUDY: Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time; your decision will not result in any loss of benefits to which 
you are otherwise entitled. 
RESULT OF THE STUDY: The results of the special study may be intimated to 
you at the end of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of Investigator           Signature of Participant 
 
Date: 
Place: 
  
 
  
PATIENT CONSENT FORM 
 
Study Detail : “A STUDY ON THE ASSOCIATION BETWEEN   
DEHYDROEPIANDROSTERONE AND FRAILTY IN 
ELDERLY” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction.  
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected.  
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to look 
at my health records, both in respect of current study and any further research that may 
be conducted in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study.  
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms.  
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo complete clinical examination and hematological 
tests.   
 
 
 
 
Signature/ thumb impression        Signature of the Investigator 
 
 
 
 
Patient’s Name & Address:        Study Investigator’s Name 
    `        Dr. P.ARAVIND BABU 
  
  
S.NO 
AGE 
(yr) 
SEX 
HEIGHT 
(cm) 
WEIGHT 
(kg) 
BMI 
(kg/m²) 
15 FT 
GAIT 
SPEED 
(sec) 
GAIT 
SPEED  
(m/s) 
PHYSICAL 
ACTIVITY 
LEVEL 
HANDGRIP 
STRENGTH 
(Kg) 
WEIGHT 
LOSS 
(>10% 
in 1 yr) 
EXHAUSTION 
(self-
reported) 
NO. OF 
FRAILTY 
COMPONENTS 
FRAILTY 
CATEGORY 
DHEAs 
LEVEL 
(µg/dl) 
1 67 MALE 165 65 23.88 5 0.91 HIGH 14 NO NO 1 INTERMEDIATE 27.2 
2 70 FEMALE 145 40 19.02 9 0.51 LOW 6 NO YES 4 FRAIL 42.6 
3 71 FEMALE 142 56 27.77 6 0.76 HIGH 8 NO NO 1 INTERMEDIATE 24.6 
4 76 MALE 152 42.5 18.40 5 0.91 LOW 12 NO YES 3 FRAIL 20.3 
5 78 FEMALE 148 45 20.54 9 0.51 LOW 3 YES YES 5 FRAIL 19.8 
6 80 MALE 160 60 23.44 5 0.91 HIGH 9 NO NO 1 INTERMEDIATE 16.7 
7 66 MALE 167 82 29.40 5 0.91 HIGH 33 NO NO 0 NON-FRAIL 26.7 
8 72 FEMALE 144 45 21.70 9 0.51 LOW 2 YES YES 5 FRAIL 23.4 
9 82 FEMALE 148 52 23.74 10 0.46 LOW 9 NO NO 3 FRAIL 22.6 
10 67 MALE 165 64 23.51 5 0.91 HIGH 13 NO NO 1 INTERMEDIATE 26.9 
11 73 FEMALE 144 57 27.49 8 0.57 HIGH 22 NO NO 1 INTERMEDIATE 23.7 
12 71 MALE 165 63 23.14 6 0.76 HIGH 30 NO NO 0 NON-FRAIL 37.8 
13 76 FEMALE 146 59 27.68 6 0.76 HIGH 7 NO YES 2 INTERMEDIATE 22.6 
14 79 MALE 170 67 23.18 5 0.91 HIGH 30 NO NO 0 NON-FRAIL 33.5 
15 82 MALE 152 47 20.34 10 0.46 LOW 6 YES YES 5 FRAIL 17.5 
16 79 FEMALE 145 65 30.92 11 0.42 LOW 5 NO YES 4 FRAIL 18.6 
17 86 FEMALE 144 45 21.70 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 25.7 
18 80 MALE 150 50 22.22 9 0.51 LOW 13 NO YES 4 FRAIL 30.4 
19 85 MALE 164 63.5 23.61 5 0.91 HIGH 9 NO NO 1 INTERMEDIATE 30.3 
20 87 FEMALE 140 38 19.39 10 0.46 LOW 4 NO NO 3 FRAIL 15 
21 68 MALE 162 62 23.62 5 0.91 HIGH 14 NO  NO 1 INTERMEDIATE 45.6 
22 82 FEMALE 157 62 25.15 9 0.51 HIGH 6 NO NO 2 INTERMEDIATE 28.9 
23 72 FEMALE 154 54 22.77 8 0.57 LOW 3 YES YES 5 FRAIL 23.9 
24 79 FEMALE 156 52 21.37 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 23.9 
25 69 FEMALE 155 49 20.40 6 0.76 HIGH 19 NO NO 0 NON-FRAIL 30.8 
MASTER CHART 
  
26 80 MALE 165 55 20.20 5 0.91 LOW 11 NO YES 3 FRAIL 16.6 
27 82 FEMALE 150 58 25.78 9 0.51 LOW 8 YES YES 4 FRAIL 60.6 
28 70 FEMALE 153 56 23.92 6 0.76 HIGH 20 NO NO 0 NON-FRAIL 32.9 
29 83 FEMALE 148 68 31.04 6 0.76 HIGH 9 NO NO 1 INTERMEDIATE 27.9 
30 74 MALE 163 57 21.45 10 0.46 LOW 14 NO YES 4 FRAIL 16.4 
31 69 FEMALE 145 47 22.35 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 56.7 
32 81 FEMALE 154 58 24.46 9 0.51 LOW 2 YES YES 5 FRAIL 64.8 
33 76 FEMALE 155 57.5 23.93 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 49.8 
34 73 MALE 155 72 29.97 9 0.51 LOW 12 NO YES 4 FRAIL 43.5 
35 68 FEMALE 155 59 24.56 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 65.7 
36 85 FEMALE 147 56 25.92 11 0.42 LOW 1 YES YES 5 FRAIL 80.5 
37 82 MALE 156 60 24.65 10 0.46 LOW 8 YES YES 5 FRAIL 15.5 
38 78 FEMALE 145 58 27.59 9 0.51 HIGH 22 NO NO 1 INTERMEDIATE 30.5 
39 86 MALE 150 58 25.78 5 0.91 LOW 8 NO YES 3 FRAIL 15 
40 87 MALE 153 50 21.36 10 0.46 LOW 6 YES YES 5 FRAIL 16.5 
41 71 MALE 156 72 29.59 5 0.91 HIGH 16 NO NO 1 INTERMEDIATE 38.9 
42 70 FEMALE 153 59 25.20 9 0.51 LOW 9 NO NO 3 FRAIL 45.8 
43 82 FEMALE 154 58 24.46 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 78.9 
44 68 MALE 165 80 29.38 5 0.91 HIGH 33 NO NO 0 NON-FRAIL 40.8 
45 78 MALE 160 60 23.44 8 0.57 HIGH 30 NO NO 1 INTERMEDIATE 34.9 
46 77 FEMALE 154 55 23.19 6 0.76 HIGH 7 NO YES 2 INTERMEDIATE 31.7 
47 66 FEMALE 154 58.5 24.67 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 83.8 
48 80 MALE 160 62 24.22 9 0.51 HIGH 12 NO NO 2 INTERMEDIATE 29.8 
49 67 MALE 165 63 23.14 5 0.91 HIGH 30 NO NO 0 NON-FRAIL 68.9 
50 70 FEMALE 152 54 23.37 6 0.76 LOW 8 NO NO 2 INTERMEDIATE 64.6 
51 78 MALE 160 62 24.22 5 0.91 HIGH 15 NO NO 1 INTERMEDIATE 32.3 
52 68 FEMALE 150 52 23.11 6 0.76 HIGH 21 YES YES 2 INTERMEDIATE 40.9 
53 80 MALE 167 65 23.31 5 0.91 HIGH 30 NO NO 0 NON-FRAIL 34.9 
54 82 MALE 153 57 24.35 9 0.51 LOW 7 YES YES 5 FRAIL 18.8 
  
55 90 MALE 152 59 25.54 10 0.46 LOW 8 NO YES 4 FRAIL 52.4 
56 69 FEMALE 158 60 24.03 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 85.6 
57 89 MALE 148 56 25.57 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 78.8 
58 78 MALE 156 63 25.89 9 0.51 LOW 5 YES YES 5 FRAIL 57.9 
59 77 FEMALE 145 45 21.40 6 0.76 HIGH 10 NO NO 1 INTERMEDIATE 48.9 
60 92 FEMALE 143 60 29.34 12 0.38 LOW 8 NO YES 4 FRAIL 15.2 
61 67 FEMALE 148 56 25.57 6 0.76 HIGH 19 NO NO 0 NON-FRAIL 84.5 
62 68 MALE 160 65 25.39 10 0.46 LOW 10 NO NO 3 FRAIL 25.5 
63 77 FEMALE 150 67 29.78 9 0.51 LOW 9 NO NO 3 FRAIL 83.9 
64 80 MALE 152 58 25.10 5 0.91 HIGH 13 NO NO 1 INTERMEDIATE 48.7 
65 76 MALE 165 79.5 29.20 5 0.91 HIGH 33 NO NO 0 NON-FRAIL 67.9 
66 78 MALE 159 63 24.92 8 0.57 HIGH 10 NO NO 2 INTERMEDIATE 54.7 
67 68 MALE 168 60 21.26 5 0.91 HIGH 30 NO  NO 0 NON-FRAIL 75.6 
68 86 MALE 155 70 29.14 8 0.57 LOW 6 NO NO 3 FRAIL 29.5 
69 85 MALE 145 52 24.73 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 79.8 
70 86 MALE 156 72 29.59 9 0.51 LOW 13 NO YES 4 FRAIL 59.9 
71 68 MALE 164 63 23.42 5 0.91 HIGH 30 NO NO 0 NON-FRAIL 77.6 
72 78 FEMALE 150 46 20.44 9 0.51 HIGH 22 NO NO 1 INTERMEDIATE 52.3 
73 69 FEMALE 142 56 27.77 6 0.76 HIGH 9 NO YES 2 INTERMEDIATE 84.5 
74 80 MALE 158 62 24.84 5 0.91 HIGH 7 NO YES 2 INTERMEDIATE 49.7 
75 70 MALE 162 65 24.77 5 0.91 HIGH 8 YES NO 2 INTERMEDIATE 65.9 
76 83 MALE 161 58 22.38 5 0.91 HIGH 30 NO NO 0 NON-FRAIL 60.9 
77 82 MALE 158 61 24.44 9 0.51 HIGH 9 NO NO 2 INTERMEDIATE 47.2 
78 79 FEMALE 150 44 19.56 6 0.76 LOW 8 NO YES 3 FRAIL 35.5 
79 81 MALE 160 67 26.17 5 0.91 LOW 8 NO NO 2 INTERMEDIATE 82.8 
80 88 MALE 161 68 26.23 10 0.46 HIGH 5 NO NO 2 INTERMEDIATE 78.8 
81 73 MALE 165 68 24.98 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 84.5 
82 68 MALE 168 72 25.51 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 87.6 
83 67 FEMALE 146 60 28.15 6 0.76 HIGH 10 NO NO 1 INTERMEDIATE 87.8 
  
 
 
84 84 FEMALE 155 70.5 29.34 6 0.76 HIGH 22 NO NO 0 NON-FRAIL 78.9 
85 80 MALE 167 67.5 24.20 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 80.5 
86 78 FEMALE 144 56 27.01 6 0.76 HIGH 22 NO YES 1 INTERMEDIATE 49.8 
87 82 MALE 163 69.5 26.16 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 80.9 
88 87 FEMALE 145 66 31.39 10 0.46 LOW 4 NO YES 4 FRAIL 16.4 
89 85 MALE 155 71 29.55 9 0.51 LOW 9 NO YES 4 FRAIL 80.9 
90 68 MALE 158 73 29.24 5 0.91 LOW 9 NO NO 2 INTERMEDIATE 89.8 
91 77 MALE 156 71.5 29.38 9 0.51 HIGH 9 NO NO 2 INTERMEDIATE 85.6 
92 78 MALE 165 67 24.61 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 83.4 
93 69 MALE 169 70.5 24.68 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 86.7 
94 86 FEMALE 148 67 30.59 9 0.51 LOW 5 NO YES 4 FRAIL 29.5 
95 82 FEMALE 162 63.5 24.20 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 83.2 
96 80 FEMALE 165 67.5 24.79 5 0.91 HIGH 31 NO NO 0 NON-FRAIL 78.6 
97 73 FEMALE 157 59.5 24.14 6 0.76 HIGH 18 NO NO 0 NON-FRAIL 80.2 
98 86 FEMALE 155 73 30.39 6 0.76 HIGH 6 NO YES 2 INTERMEDIATE 47.2 
99 72 MALE 156 72 29.59 9 0.51 LOW 10 NO NO 3 FRAIL 82.5 
100 85 FEMALE 154 72.5 30.57 9 0.51 HIGH 4 NO NO 2 INTERMEDIATE 79.8 
